The Impact of the Plasma Protein Corona on the Adhesion Efficiency of Drug Carriers to the Blood Vessel Wall. by Sobczynski, Daniel J.
  
 
 
 
THE IMPACT OF THE PLASMA PROTEIN CORONA ON THE ADHESION 
EFFICIENCY OF DRUG CARRIERS TO THE BLOOD VESSEL WALL 
 
by 
 
Daniel J. Sobczynski 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Chemical Engineering) 
in the University of Michigan 
2016 
 
 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
 Associate Professor Lola Eniola-Adefeso, Chair 
 Professor Jennifer J. Linderman 
 Assistant Professor Greg M. Thurber 
 Associate Professor Angela Violi 
 
 
 
 
 
 
  
 
 
 
 
© Daniel J. Sobczynski 2016 
All Rights Reserved 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ii 
 
 DEDICATION 
 
To my family and friends, thank you for all your love and support throughout this 
experience; I am forever grateful. 
 
 
  
iii 
 
ACKNOWLEDGEMENTS 
  
First, I would graciously like to thank my advisor, Dr. Eniola-Adefeso, for 
mentoring me throughout my graduate career and having me in her lab. My graduate 
experience in Lola’s lab has not only taught me a great deal about scientific research but 
also how to grow as a professional. I have always felt that Lola has a sincere investment in 
her students and recognizes the unique talents of each individual student, and I am glad to 
have been a part of that experience. I am excited to see new research publications from the 
lab in the future. 
 Second, I would also like to extend a special thank you to my committee: Dr. 
Eniola, Dr. Linderman, Dr. Thurber, and Dr. Violi. I am honored to have you serve on my 
committee. In addition, I am thankful for the helpful discussions and feedback upon 
completion of my PhD. 
 Third, thanks to all the members of the lab for help and assistance on various 
research projects: Ploy Charoenphol, Alex Thompson, Peter Onyskiw, Michael Heslinga, 
Katawut Namdee, Ted Zaroff III, Mariana Carrasco-Teja, Hanieh Safari, Margaret Fish, 
Genesis Lopez, William Kelly, Cathy Fromen and several others with whom I’ve worked. 
I would also like to thank Liang Zhang, Cornelius Cilliers, Dr. Fei Wen, Mason Smith, and 
Brett Hill for their helpful discussions about proteins and experimental techniques. Also, I 
am especially grateful for all participants who donated blood for my research experiments.  
  
iv 
 
 Lastly, I would like to thank my family and friends for their tremendous support 
throughout this challenging experience. Your love has meant so much to me, and I hope 
you know that.  
  
  
v 
 
TABLE OF CONTENTS 
 
DEDICATION .................................................................................................................... ii 
ACKNOWLEDGEMENTS ............................................................................................... iii 
LIST OF TABLES ...............................................................................................................x 
LIST OF FIGURES ........................................................................................................... xi 
LIST OF ABBREVIATIONS ............................................................................................xx 
ABSTRACT ..................................................................................................................... xxi 
CHAPTER 1: INTRODUCTION .....................................................................................1 
1.1 Dissertation Outline....................................................................................................1 
1.2 Background ................................................................................................................2 
1.2.1 Vascular targeting ................................................................................................2 
1.2.2 Key parameters for designing VTCs ...................................................................3 
1.2.2.1 Drug carrier type .......................................................................................... 3 
1.2.2.2 Targeting system .......................................................................................... 5 
1.2.2.3 Hemodynamic effects .................................................................................. 6 
1.2.3 Translation of in vitro blood flow assays to biodegradable systems ...................8 
1.2.4 The plasma protein corona ................................................................................11 
1.2.4.1 Key parameters governing plasma protein corona formation .................... 12 
1.2.4.2 Role of plasma protein corona in uptake, circulation time, and biodistribution
................................................................................................................................ 15 
  
vi 
 
CHAPTER 2: MATERIALS AND METHODS .......................................................... 25 
2.1 Particles used for in vitro flow assays ..................................................................... 25 
2.1.1 Biodegradable particles .................................................................................... 25 
2.1.1.1 PLGA microparticle fabrication ................................................................ 25 
2.1.1.2 Purchased nanoparticles ............................................................................. 25 
2.1.2 Non-biodegradable particles ............................................................................. 26 
2.2 Particle characterization .......................................................................................... 26 
2.2.1 Concentration.................................................................................................... 26 
2.2.2 DLS sizing ........................................................................................................ 26 
2.2.3 Zeta potential .................................................................................................... 26 
2.2.4 Surface ligand conjugation ............................................................................... 27 
2.2.4.1 NeutrAvidin, albumin conjugation ............................................................ 27 
2.2.4.2 sLea, anti-ICAM-1, and polyethylene glycol (PEG) conjugation .............. 28 
2.2.5 sLea, anti-ICAM-1, PEG and albumin density quantification .......................... 28 
2.3 HUVEC cell culture ................................................................................................ 29 
2.4 Blood preparation .................................................................................................... 30 
2.4.1 Whole blood ..................................................................................................... 30 
2.4.2 Plasma ............................................................................................................... 30 
2.4.3 Serum ................................................................................................................ 30 
2.4.4 Immunoglobulin/albumin depleted plasma and serum ..................................... 30 
2.4.5 IgG depletion and isolation............................................................................... 31 
2.4.6 IgA depletion and isolation............................................................................... 31 
2.4.7 RBCs-in-Buffer ................................................................................................ 31 
  
vii 
 
2.4.8 Reconstituted blood: RBCs-in-VB, RBCs-in-Serum ....................................... 32 
2.4.9 Hematocrit ........................................................................................................ 32 
2.5 Parallel plate flow chamber assays.......................................................................... 32 
2.5.1 Laminar flow assays ......................................................................................... 32 
2.5.2 Pulsatile flow assays ......................................................................................... 33 
2.5.3 Plasma depleted soaking assays ....................................................................... 33 
2.6 SDS-PAGE .............................................................................................................. 33 
2.7 ELISA...................................................................................................................... 34 
2.8 Mass spectrometry................................................................................................... 35 
2.9 Data analysis ........................................................................................................... 35 
CHAPTER 3: PLASMA PROTEIN CORONA MODULATES THE VASCULAR 
WALL INTERACTION OF DRUG CARRIERS IN A MATERIAL- AND DONOR- 
SPECIFIC MANNER ..................................................................................................... 37 
3.1 Introduction ............................................................................................................. 39 
3.2 Results ..................................................................................................................... 41 
3.2.1 Evaluation of PLGA adhesion in a variety of blood flow media ..................... 41 
3.2.2 Evaluation of human blood donor on PLGA adhesion ..................................... 44 
3.2.3 Evaluation of the effect of flow magnitude and profile on PLGA blood flow 
adhesion ..................................................................................................................... 49 
3.2.4 Evaluation of potential plasma protein effects on other VTC material types .. 51 
3.2.5 Characterization of protein adsorption on PLGA versus PS spheres ............... 56 
3.3 Discussion ............................................................................................................... 58 
3.4 Conclusion ............................................................................................................... 67 
  
viii 
 
CHAPTER 4: PLASMA IMMUNOGLOBULINS DRIVE CORONA-INDUCED 
NEGATIVE ADHESION EFFECTS ON PLGA DRUG CARRIERS ...................... 71 
4.1 Introduction ............................................................................................................. 72 
4.2 Results ..................................................................................................................... 73 
4.2.1 Assessment of immunoglobulin depletion kit specificity and efficiency ......... 73 
4.2.2 Evaluation of PLGA particle adhesion pre-soaked in depleted plasma ........... 76 
4.2.3 Evaluation of PLGA particle adhesion pre-soaked in Igs depleted plasma with 
re-addition of specific Ig proteins .............................................................................. 78 
4.3 Discussion ............................................................................................................... 80 
4.4 Conclusions ............................................................................................................. 81 
CHAPTER 5: IMPACT OF BIODEGRADABLE MATERIAL TYPE ON 
CORONA-INDUCED NEGATIVE ADHESION OF DRUG CARRIERS IN HUMAN 
BLOOD FLOW ............................................................................................................... 83 
5.1 Introduction ............................................................................................................. 84 
5.2 Results ..................................................................................................................... 85 
5.2.1 Evaluation of the adhesion efficiency of various VTCs in human blood   flow
 ................................................................................................................................... 85 
5.2.2 Evaluation of targeting ligand density and type on blood flow adhesion of 
biodegradable VTCs .................................................................................................. 85 
5.2.3 Characterization of zeta potential and protein corona profile on VTCs ........... 87 
5.2.4 Evaluation of covalent attachment of albumin to improve PLGA adhesion 
efficiency in human blood flow ................................................................................. 90 
5.3 Discussion ............................................................................................................... 90 
  
ix 
 
5.4 Conclusions ............................................................................................................. 94 
CHAPTER 6: THE IMPACT OF ANTICOAGULANT ON CORONA-INDUCED 
NEGATIVE ADHESION ON DRUG CARRIERS IN BLOOD FLOW ....................98 
6.1 Introduction ..............................................................................................................99 
6.2 Results ....................................................................................................................100 
6.2.1 Impact of anticoagulant on the adhesion efficiency of various VTC 
materials....................................................................................................................100 
6.2.2 Evaluation of HUVEC adhesion of various VTCs in anticoagulant-free WB   
flow ...........................................................................................................................101 
6.2.3 Impact of ligand density in mitigating plasma-associated VTC adhesion 
reduction ...................................................................................................................104 
6.2.4 Evaluation of differences in VTC protein corona relative to blood 
characteristic .............................................................................................................104 
6.3 Discussion ..............................................................................................................106 
6.4 Conclusion ..............................................................................................................112 
CHAPTER 7: CONCLUSIONS, FUTURE STUDIES, AND COMMENTS .......... 116 
7.1 Conclusions and Major Contributions................................................................... 116 
7.2 Future studies ........................................................................................................ 119 
7.3 Concluding thoughts, comments, and potential directions for the field .................121
  
x 
 
LIST OF TABLES 
 
Table 3.1 Particle size measurements via dynamic light scattering (DLS)………………..41  
Table 3.2 Zeta potential measurement for 2 µm particles...………..…..............................51  
Table 3.3 Unique peptides found on PLGA particles in low-HUVEC binding plasma.......60 
Table 3.4 Unique peptides found on PLGA particles in low-HUVEC binding donor plasma 
and absent from PLGA particles exposed to high-HUVEC binding donor plasma    
……………………………………………………………………........................61 
Table 4.1 Assessment of Ig concentration post depletion column/bead exposure……......74 
Table 5.1 Particle size characterization……………..........................................................85 
Table 6.1 VTC ligand density quantification.…………………………………………...100 
  
xi 
 
LIST OF FIGURES 
 
Figure 1.1 HUVEC adhesion of sLea-targeted (~800 sites/µm2) PS and PLGA 2 µm 
particles in human whole blood flow in a parallel plate flow chamber (PPFC) at 200 
s-1 for 5 minutes at a concentration of 5 × 105 
particles/mL…………………….…………………………………………………9 
Figure 3.1 Summary of the adhesion of PLGA spheres from flow of buffer, plasma, and 
blood to an activated endothelial cell monolayer. (A) A depiction of particle 
margination in buffer, plasma, and blood flow. Binding density after 5 min of flow 
for (B) 4.6 μm, (C) 1.4 μm and (D) 330 nm sLea-coated PLGA particles to activated 
HUVEC monolayer from laminar buffer, plasma, or whole blood at 200 s-1. Particle 
concentration = 5 × 105 particles/mL for 4.6 and 1.4 μm data and 1 × 106 
particles/mL for the 330 nm particles. sLea density = 1,700 +/- 100 sites/μm2 (SEM) 
surface for 4.6 μm, 1500 +/- 100 sites/μm2 (SEM) for 1.4 μm and 9,000 +/- 400 
sites/μm2 (SEM) for 330 nm particles. N = 3 distinct donors (donors A, B, and C). 
……………………………………………………………………………………43  
Figure 3.2 Phase and fluorescence images of small PLGA spheres. Phase image of 1.4 μm 
PLGA particles in PBS+/+ (A) and plasma (B), and fluorescence image of 330 nm 
PLGA in PBS+/+ (C) and plasma (D).  Particles were added to the desired medium 
for 5 min in static after which a small amount of the particle solution is placed on a 
coverslip for imaging.  All images shown were taken at a 40X magnification. Scale 
bar = 10 μm………………………………………………………………………45 
  
xii 
 
Figure 3.3 Sample images of activated HUVEC monolayers exposed to PLGA under 
different flow types. Phase image of 1.4 μm sLea-coated PLGA spheres bound to 
IL1-β-activated HUVEC monolayer after 5 min of flow of particles in (A) RBC-in-
Buffer, (B) whole blood, and (C) plasma at 200 s-1. Image taken at 20X 
magnification. sLea density =  1500 +/- 100 sites/μm2 (SEM). Particle concentration 
= 5e5 particles/mL. Scale bar = 20 μm……………………………………………46 
Figure 3.4 Particle adhesion to activated HUVEC in laminar flow of individual donor 
plasma and blood at 200 s-1. Adhesion of (A) 4.6 μm and (B) 330 nm PLGA spheres 
at high sLea density and (C) 4.6 μm spheres at low sLea density.  Buffer and viscous 
buffer controls are shown on the left side of the graph. sLea density = 1,800 +/- 100 
sites/μm2 (SEM) in (A), 9,000 +/- 300 sites/μm2 (SEM) in (B) and 130+/-10 
sites/μm2 (SEM) in (C). Adhesion data collected after 5 min of flow time. Particle 
concentration = 5 × 105 particles/mL for 4.6 μm data and 1 × 106 particles/mL for 
the 330 nm particles. N = 2 distinct assays for each donor. ns = Not significant at 
99% confidence interval………………………………………………………….48  
Figure 3.5 Average adhesion of 1.4 μm and 330 nm sLea–coated PLGA spheres to activated 
HUVEC in buffer, viscous buffer, plasma, blood, and RBC-in-buffer flows. Panels 
(A) and (B) shows the adhesion of 1.4 μm spheres in laminar shear at 500 s-1 and 
pulsatile flow with peak shear at 1000 s-1, respectively.  Panels (C) and (D) show 
the adhesion of 330 nm PLGA spheres in laminar shear at 500 s-1 and pulsatile flow 
with peak shear at 1000 s-1, respectively. sLea density = 1700 +/- 100 sites/μm2 
(SEM) for 1.4 μm spheres and  7000 +/- 300 sites/μm2 (SEM) for 330 nm spheres. 
Particle concentration = 5 × 105 particles/mL for 1.4 μm data and 1 × 106 
  
xiii 
 
particles/mL for the 330 nm particles.  Laminar flow was run for 5 min and pulsatile 
flow for 15 min.  N = 3 distinct trials (donors) for the plasma and blood flow assays. 
ns = Not significant at 99% confidence interval…………………………………50  
  Figure 3.6 Adhesion of sLea–coated PS spheres or anti-ICAM-coated PLGA spheres to 
activated HUVEC under various flow conditions. (A) Adhesion of 5 μm sLea–
coated PS spheres in laminar whole blood and buffer flows to activated HUVEC at 
200 s-1 for 7 human subjects. N = 2 (distinct trials) for each blood bar. (B) Average 
adhesion of 4.6 μm anti-ICAM-coated PLGA spheres to activated HUVEC from 
laminar buffer, plasma, or whole blood flow of three low PLGA binding donors at 
200 s-1. Laminar flow was run for 5 min. Particle concentration in flow = 5 × 105 
spheres/mL. sLea density = 1,800 +/- 200 sites/μm2 (SEM) and anti-ICAM-1 
density = 3500 +/- 500 sites/μm2 (SEM). N = 3 distinct trials (donors) for the plasma 
and blood flow assays. ns = Not significant at 99% confidence 
interval…………………………………………………………………………...52  
Figure 3.7 Adhesion of 500 nm sLea-coated PLGA, polystyrene, and silica spheres to 
activated HUVEC in blood flow relative to RBCs-in-VB. Site densities (#/µm2) 
were obtained as follows: PLGA 3200 +/- 900; PS 3100 +/- 20; Si 4400 +/- 200. 
Particle concentration in flow = 1 × 106 spheres/mL. *= significant at 99% 
confidence relative to PLGA trial, **= significant at 99% relative to PS trial.....53  
Figure 3.8 Adhesion of PEGylated and non-PEGylated 1.4 μm sLea-targeted spheres to 
HUVEC in laminar buffer or whole blood flow at 200 s-1 (5 min).  A PEG density 
of 16,000 site/μm2 estimated to be the brush conformation is used.  sLea density = 
1,800 +/- 200 sites/μm2 for both PEGylated and un-PEGylated particles.  Particle 
  
xiv 
 
concentration in flow = 5 × 105 particles/mL. ns = Not significant at 99% 
confidence interval………………………………………………………………55   
Figure 3.9 Analysis of proteins adsorbed to particle surfaces as a function of material type 
and plasma incubation time.  (A) SDS-gel electrophoresis analysis of proteins 
adsorbed on PS (5 μm) and PLGA (5 μm) spheres after 1 hr incubation in plasma. 
(Lane 1) Molecular weight standard. Proteins adsorbed onto particle surfaces were 
analyzed from the following conditions: PLGA soaked in a high (Lane 2) and low 
(Lane 3) HUVEC binding donor plasma; PS soaked in a low (Lane 4) and high 
(Lane 5) HUVEC binding donor; and PLGA (Lane 6) and PS (Lane 7) soaked in 
1% BSA solution. The protein profile in a 0.4% plasma of the low (Lane 8) and 
high (Lane 9) HUVEC binding donor was run as well. (B) Correlation of the buffer 
flow (200 s-1 laminar) adhesion of plasma opsonized PLGA (4.6 μm) spheres as a 
function of plasma incubation time (bottom) with the presence/development of a 
protein band at ~150 kDa in the protein corona of PLGA spheres as a function of 
time as observed with SDS-gel electrophoresis analysis (top).  (C) A depiction of 
differential plasma protein (PP) adsorption on PLGA and PS spheres……………59 
Figure 3.10 Adhesion of 5 μm PLGA particles at a low sLea density (200 +/- 200 sites/μm2) 
to HUVEC in laminar buffer flow at 200 s-1 (5 min). Particles were soaked for 1 hr 
in 1 mL in PBS (0% plasma) or in a low HUVEC binding donor plasma at 5%, 
25%, or 25% with depletion of albumin and immunoglobulins prior to flow in 
buffer for 5 min. * = Not significant at 99% confidence interval relative to PBS 
control…………....................................................................................................62 
 
  
xv 
 
Figure 4.1 A) ELISA Quantification of plasma IgG, IgM, and IgA1 fractions in the eluted 
product from the Protein A column (IgG*), IgA depletion column (IgA*), and in 
the case where IgG depleted plasma was exposed to the IgA depletion column 
(IgA* x-IgG). B) SDS-PAGE of IgG depleted plasma and IgG*: Lane 1 – standard, 
Lane 2 – 2% plasma, Lane 3 – 2% plasma (IgG depleted), and Lane 4 – IgG*. C) 
SDS-PAGE of IgA depleted plasma and IgA*: Lane 1 – standard, Lane 2 – 2% 
plasma, Lane 3 – 2% plasma (IgA depleted), and Lane 4 – 
IgA*…………………………………………………………………..…………………...75 
Figure 4.2 A) Adhesion of slea-targeted PLGA particles soaked for 1 hr in 25% plasma (No 
depletion), 25% IgG depleted plasma, 25% IgG + IgA depleted plasma, 25% Igs 
depleted plasma, prior to a parallel plate flow chamber assay in RBCs-in-VB (38% 
hematocrit) at 200 s-1. * = p <0.01 compared to 25% (No depletion) trial, 
concentration 1 × 106 # particles/mL, n = 3 (averaged across donors N,F,D,V). B) 
PLGA particle adhesion in the same mediums as (A) but on a donor-to-donor basis. 
C) ELISA of IgG concentration in the various donors................................................77 
Figure 4.3 A) Adhesion of slea-targeted PLGA particles soaked for 1 hr in 25% plasma (No 
depletion), 25% Igs depleted plasma and  25% Igs depleted plasma + 5 mg/mL 
IgG*, 1 mg/mL IgA*, IgA* x-IgG, and commercial IgM prior to a parallel plate 
flow chamber assay in RBCs-in-VB (38% hematocrit) at 200 s-1. * = p <0.01 
compared to 25% (No depletion) trial, concentration 1 × 106 # particles/mL. B) 
ELISA testing of IgA1 and IgM concentrations for different donors. C) SDS-PAGE 
of the 25% plasma solutions PLGA particles were soaked with prior to flow assay; 
Lane 1: molecular weight ladder, Lane 2: no depletion, Lane 3: IgG depleted, Lane 
  
xvi 
 
4: IgA depleted, Lane 5: Igs depleted, Lane 6: Igs depleted + 5 mg/mL IgG*, Lane 
7: Igs depleted + 1 mg/mL IgA*, Lane 8: Igs depleted + 5 mg/mL IgG* + 1 mg/mL 
IgA*, Lane 9: IgA + IgG depleted…………………………...………….………..79 
Figure 5.1 HUVEC adhesion (% relative to RBCs-in-VB Control) for PLGA, PLA, PCL, 
and PS VTCs in whole blood after 5 min of flow at a shear rate of 200 s-1. The site 
densities with standard error were calculated: PLGA 8600 +/- 600; PLA 7500 +/- 
50; PCL 7100 +/- 1200; PS 9200 +/- 300. Particle concentration was fixed to 1 × 
106 particles/mL………………………………………………………………….86 
Figure 5.2 A) HUVEC adhesion (% relative to RBCs-in-VB Control) for PLGA, PLA, 
PCL, and PS VTCs in whole blood after 5 min of flow at a shear rate of 200s-1. Site 
densities for A) were obtained as follows: PLGA 15300 +/- 900; PLA 12300 +/- 
100; PCL 14500 +/- 700. B) Effect of targeting ligand type on adhesion efficiency, 
with the following site densities (#/µm2): sLea, (All materials) 3000 +/- 500; anti-
ICAM-1, PLGA 3700 +/- 200; PLA 4000 +/- 100; PCL 3200 +/- 20. C) HUVEC 
adhesion of high density anti-ICAM-1 coated PLGA particles (19300 +/- 500) 
versus 3700 +/- 200 sites/µm2. Particle concentration was fixed to 1 × 106 
particles/mL in all assays………………………………………………………...88  
Figure 5.3 A) Zeta potential measurements for sLea-coated VTCs of PLGA, PLA and PCL. 
B) SDS-PAGE of surface bound protein coronae formed on PLGA, PCL, and PLA 
VTCs exposed to VB and ACD plasma. Lane 1: molecular weight standard, Lane 
2: PLGA corona from VB soak, Lane 3: PCL corona from VB soak, Lane 4: PLA 
corona from VB soak, Lane 5: PLGA corona from plasma soak, Lane 6: PCL 
corona from plasma soak, Lane 7: PLA corona from plasma soak. C)  SDS-PAGE 
  
xvii 
 
of surface bound protein coronae formed on ~5 µm PLGA and PS VTCs exposed 
to VB and ACD plasma. Lane 1: molecular weight standard, Lane 2: PS corona in 
low HUVEC binding donor plasma, Lane 3: PLGA corona from high HUVEC 
binding donor plasma, Lane 4: PLGA corona in high HUVEC binding donor 
plasma, Lane 5: PS corona from high HUVEC binding donor 
plasma..………………………………………………………….……….............89 
Figure 5.4 HUVEC adhesion (% relative to RBCs-in-VB Control) for PLGA anti-ICAM-
1 particles (6600 +/- 50 sites/µm2) along with PLGA anti-ICAM-1 particles 
covalently linked with human serum albumin (HSA) with 8000 +/- 140 anti-ICAM-
1 sites/µm2. ~3600 sites of human serum albumin were covalently coupled to the 
PLGA-HSA-anti-ICAM-1 particles confirmed via an anti-human Albumin-FITC 
antibody………………………………………………………….………............91 
Figure 6.1 PPFC assay with VTCs in various anticoagulants: HUVEC adhesion (% relative 
to RBCs-in-VB Control) for PLGA, PLA, PS, Si, and PCL VTCs in ACD WB, 
heparinized WB, and RBCs-in-Serum relative to RBCs-in-VB after 5 min of flow 
at a shear rate of 200s-1. Particle concentration was fixed to 1 x 106 particles mL-1. 
* = p<0.01 relative to ACD-WB trial for given material via one-way ANOVA with 
Tukey post-test. n ≥ 4. ** = p<0.01 relative to heparinized WB trial for given 
material via one-way ANOVA with Tukey post test…………………………..102 
Figure 6.2 PPFC assay with VTCs in ACF WB: HUVEC adhesion (% relative to RBCs-
in-VB Control) for PLGA, PLA, PS, Si, and PCL VTCs in Anticoagulant-free WB 
relative to RBCs-in-VB after 5 min of flow at a shear rate of 200s-1. Particle 
  
xviii 
 
concentration was fixed to 1 x 106 particles mL-1. * = p<0.01 relative to 
Anticoagulant-free WB trials relative to all other VTC materials……………..103 
Figure 6.3 PPFC assay with high ligand density PLGA VTCs: HUVEC adhesion (% 
relative to RBCs-in-VB Control) for high ligand density PLGA VTCs (~15,000 
sites/µm2) in ACD WB, heparinized WB, RBCs-in-Serum, and Anticoagulant-free 
WB after 5 min of flow at a shear rate of 200s-1. Particle concentration was fixed to 
1 x 106 particles mL-1. * = p<0.01 relative to ACD-WB trial via one-way ANOVA 
with Tukey post-test. n ≥ 4. ** = p<0.01 relative to heparinized WB trial via one-
way ANOVA with Tukey post-test……………………………………………..105  
Figure 6.4 PPFC assay with high ligand density PCL VTCs: HUVEC adhesion (% relative 
to RBCs-in-VB Control) for high ligand density PCL VTCs (~7,000 sites/µm2) in 
ACD WB, heparinized WB, and RBCs-in-Serum after 5 min of flow at a shear rate 
of 200s-1. Particle concentration was fixed to 1 x 106 particles mL-1. * = p<0.01 
relative to ACD-WB trial via one-way ANOVA with Tukey post-test. n ≥ 4. ** = 
p<0.01 relative to heparinized WB trial via one-way ANOVA with Tukey post-
test……………………………………………………………………………...108  
Figure 6.5 Zeta potential measurements for sLea-coated VTCs of various materials. VTCs 
were soaked in the various medium (viscous buffer, ACD plasma, heparinized 
plasma, serum) and washed with D.I. water. Measurements were then performed in 
D.I. water using a Malvern Zetasizer instrument. Concentration ranged from 0.65 
– 2.5 × 107 particles/mL…………………….....................................................109  
Figure 6.6 SDS-PAGE: Characterization of surface bound protein coronae formed on 
PLGA VTCs exposed to VB, plasma (ACD, heparin), and serum. Lane 1: molecular 
  
xix 
 
weight standard, Lane 2: corona from VB soak, Lane 3: corona from ACD plasma 
soak, Lane 4: corona from heparinized plasma soak, Lane 5: corona from serum 
soak ……………………………………………………………………………110  
 
  
xx 
 
LIST OF ABBREVIATIONS 
 
VTC  Vascular targeted carrier 
HUVEC Human umbilical vein endothelial cells 
PLGA  Poly(lactic-co-glycolic acid) 
PLA  Poly(lactic acid) 
PCL  Polycaprolactone 
WBC  White blood cells 
sLea  Sialyl-Lewis A 
RBC  Red blood cells 
ACD  Acid-citrate-dextrose 
PEG  Poly(ethylene glycol) 
PVA  Polyvinyl alcohol 
VB  Viscous buffer 
PPFC  Parallel plate flow chamber 
PS  Polystyrene 
NP  Nanoparticle 
HSA  Human serum albumin 
Si  Silica 
Igs  Immunoglobulins 
WB  Whole blood
  
xxi 
 
  
ABSTRACT 
 
THE IMPACT OF THE PLASMA PROTEIN CORONA ON THE ADHESION 
EFFICIENCY OF DRUG CARRIERS TO THE BLOOD VESSEL WALL 
 
by 
 
Daniel J. Sobczynski 
 
Chair: Omolola  Eniola-Adefeso 
 
 Upon injection of vascular-targeted drug carriers into the bloodstream, plasma 
proteins rapidly coat the carrier surface, forming a plasma protein corona. This corona is 
dependent on a host of parameters, including physicochemical particle properties and the 
plasma composition. Although several studies have identified key roles of the protein 
corona regarding circulation time, clearance, and biodistribution, the role of the plasma 
protein corona on the adhesion efficiency of vascular-targeted carriers (VTCs) to inflamed 
human umbilical vein endothelial cells (HUVECs) in human blood flow remains relatively 
unknown. In this dissertation, it is observed that the plasma protein corona exerts a negative 
effect on the adhesion of drug carriers in blood flow; however, the extent of these 
observations depend on a host of parameters including drug carrier material type, targeting 
ligand density, flow profile, plasma exposure time, and plasma anticoagulant. Furthermore, 
the magnitude of the corona-induced negative adhesion effects is shown to be heavily 
linked to the adsorption of immunoglobulin antibodies in plasma. This work has a variety 
of important implications for the intelligent design of VTCs. First, the fact that 
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immunoglobulins heavily dictate adhesion reduction of drug carriers offers insight into 
specific directions to limit the effects of the protein corona. Specifically, tuning the corona 
to avoid adsorption of these proteins or coating with non-fouling dysopsonin proteins offers 
a method to maintain targeting efficiency in the presence of corona formation. Second, this 
work may explain why current targeted drug delivery systems often exhibit poor 
accumulation to the target site based on the large reduction of particles upon exposure to 
human plasma. Third, this work could be used to develop strategies to predict or “diagnose” 
a specific drug carrier based on its protein corona profile, hopefully leading to more 
successful translations of drug delivery systems to the market. Overall, this work shows 
that protein corona is a critical parameter when designing high-efficient targeted drug 
carriers and may be exploited or eliminated to achieve maximum adhesion specificity in 
vivo.  
 1 
 
CHAPTER 1: INTRODUCTION 
1.1 Dissertation Outline 
 The focus of this dissertation is on the impact of plasma protein adsorption on the 
adhesion efficiency of biodegradable polyester VTCs to HUVECs in human blood flow. 
In particular, this thesis probes a variety of parameters which are known to affect the 
composition of the protein corona, and thus, could play a role in modulating the adhesion 
efficiency of VTCs in blood flow. In addition, this work seeks to identify specific protein 
which may be causing the observed effects on VTC adhesion efficiency.  
 Chapter 1 provides the motivation to consider vascular targeting as a therapeutic 
strategy, highlights important VTC design criteria (particularly interaction with blood 
flow), reviews recent studies on VTC localization and adhesion in blood flow, and 
establishes the basis for considering plasma as an important parameter that prescribes VTC 
adhesion via experiments with PS and PLGA particles. In addition, the current 
understanding of plasma protein in drug delivery is reviewed as well as important 
parameters which affect the corona formation. Lastly, the focus and outline of this 
dissertation is discussed.  
 Chapter 2 describes the materials and methods used to complete the experimental 
studies in this work.  
 Chapter 3 seeks to elucidate the role of plasma protein adsorption on the adhesion 
efficiency of PLGA VTCs.  In particular, various particle (size, ligand density) and blood 
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flow properties (shear rate, human donor) are explored to understand which parameters are 
critical in determining the extent of the negative plasma adhesion effect on PLGA particles.  
 Chapter 4 seeks to further develop understanding the source of the initially 
observed plasma effect with PLGA, particularly its association with immunoglobulin (Ig) 
proteins. Adhesion assays are performed involving presoaking of particles in plasma 
depleted of specific proteins, particularly immunoglobulin G (IgG), with the intent to 
pinpoint which proteins could be causing the negative adhesion effect. In addition, IgA, 
IgM, and IgG solutions are re-constituted to plasma depleted of all immunoglobulins and 
it is observed that IgA plays a dominant role in re-establishing corona-induced negative 
adhesion.  
 Chapter 5 explores the blood flow adhesion of other biodegradable polyesters 
besides PLGA, including PLA and PCL for different targeting ligands and densities.    
 Chapter 6 focuses on the role of plasma anticoagulant—an important parameter 
which can significantly affect plasma composition and thus the VTC protein corona. In 
addition, understanding how anticoagulant may prescribe VTC adhesion is critical in 
helping to bridge in vitro assays with VTC expectations in vivo, where anticoagulant is 
absent.  
 Chapter 7 provides ideas for future studies aimed at exploiting the plasma protein 
corona as well as a general outlook on new directions for the role of the protein corona in 
vascular targeting.  
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1.2 Background 
1.2.1 Vascular targeting 
Targeting drugs to the site of disease (e.g., vascular endothelium, tumor mass) is of 
great interest to several types of diseases, including atherosclerosis and cancer. It has 
enormous potential to maximize therapeutic efficacy, reduce required therapeutic dosages, 
and greatly mitigate side effects over systemic drug delivery. This “targeted” delivery 
approach has been rigorously applied to cancer and cardiovascular diseases, given the 
concern over deleterious side effects of current treatments such as statins and 
chemotherapeutics1–5. Vascular targeting refers to specifically targeting the diseased 
endothelium and represents an incredible opportunity for disease intervention given the 
ubiquitous involvement of vascular dysregulation (e.g. inflammation, angiogenesis) in 
several diseases6–8.  Furthermore, the employment of targeted therapies designed to achieve 
localized delivery, facilitated via particulate drug vehicles, has shown growing promise in 
both preclinical and clinical models. However, there still remains a need to improve on 
these approaches, as at most only ~3% of “targeted” therapies actually reach the diseased 
region of interest9.  
1.2.2 Key parameters for designing VTCs 
A variety of parameters must be considered when designing a VTC. First, the VTC 
chosen needs a high drug loading capacity and provides sustained, controlled release. 
Second, the VTC needs to be equipped with an appropriate targeting ligand based on the 
biomarkers overexpressed in the diseased cell. Third, and vitally important, the VTC must 
navigate the complex blood flow environment, evade immune clearance, bind to the 
diseased vascular endothelium, and locally release therapeutic cargo or be internalized first.  
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1.2.2.1 Drug carrier type 
A variety of drug carrier types have been proposed for use in drug delivery and 
imaging applications. Some common types include soluble carriers, lipid-based carriers, 
and inorganic and polymer matrix nanoparticles6. Soluble carriers such as antibodies and 
modified plasma proteins maintain the advantage of easily reaching the tissue space, but 
are limited in their loading capacity and may jeopardize the activity of the drug since 
covalent linkages are commonly required10. Lipid-based carriers include liposomes and 
micelles. Liposomes are composed of a phospholipid bilayer structure and have shown 
improved bioavailability over conventional capsule formulations due to increased 
targeting/loading capability compared to soluble carriers. However, one concern of 
liposomes is their stability and lifetime in blood flow, where high shear forces are 
consistently at play, particularly in larger blood vessels. Liposomes have shown success in 
the market for cancer therapy and Doxil® is an example of chemotherapeutic liposomal 
formulation11. Micelles are nano-sized colloids composed of a hydrophobic core and 
hydrophilic shell and have proven useful in loading poorly aqueous soluble bioactive 
agents. Simultaneous plaque imaging and drug delivery has been achieved using dual 
function capabilities of micelles12. One disadvantage is the storage stability and limited 
polymer materials which are considered non-toxic to fabricate micelles. Nanoparticles 
represent a major class of drug carriers which are of special interest, evidenced by the vast 
array of literature characterizing their properties and testing their applications in preclinical 
models of various diseases11,13. Inorganic nanoparticles, such as gold, maintain robust 
blood stability and have been shown to cause minimal cell toxicity14. One limitation of 
these types of nanoparticles is the feasibility in achieving sustained release, since this 
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requires tuning of pore sizes10. Polymer-based nanoparticles are also of great importance 
to the field of drug delivery, and these include dendrimers, polymersomes, and solid-matrix 
nanoparticles. Dendrimers have shown success in extending the circulation time of 
antithrombotic agents; however, toxicity concerns have been raised regarding dendimer 
use. Polymersomes have a similar structure as liposomes and maintain the benefit of 
membrane flexibility and integrity. Solid-matrix nanoparticles, such as biodegradable poly 
(lactic-co-glycolic) acid (PLGA) nanoparticles are highly attractive for their robust 
stability, high level of control of loading/release properties, and overall versatility in tuning 
physical properties such as size, shape, and surface functionalization15. One disadvantage 
of biodegradable polyester nanoparticles, such as PLGA, includes the acidic environment 
produced as the particle degrades, which could affect the drug activity, but use of agents 
such as trehalose can offer solutions to this problem16. This thesis will focus primarily on 
the use of biodegradable polymer nanoparticles as potential VTCs.    
1.2.2.2 Targeting system 
Vascular targeting employs an active targeting approach. This involves a specific 
receptor-ligand interaction, as opposed to passive targeting, which is based on filtering 
nanoparticles to various tissues due to the size of endothelial fenestrations17. The receptor-
ligand system of interest depends on the disease. Identification of suitable molecular targets 
has been greatly advanced via in vivo phage display, allowing for a better understanding of 
diseases and optimal targets in treating vascular diseases18. For example, a primary feature 
of cardiovascular diseases is a chronic inflammatory response of the arteries6. 
Inflammation of the arterial wall causes the upregulation of proteins, including cell 
adhesion molecules and selectins. These inflammatory proteins overexpressed on the 
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diseased vascular wall offer great opportunities to exploit for vascular-targeted therapies19. 
In particular, this work will focus on targeting E-selectin, which has been shown to exhibit 
high upregulation during inflammation and low background levels on quiescent endothelial 
cells20.      
1.2.2.3 Hemodynamic effects 
VTCs will immediately come into contact with blood flow upon intravenous 
injection. Blood is a complex fluid consisting of red blood cells (RBCs), leukocytes or 
white blood cells (WBCs), platelets, and protein-rich plasma fluid. Furthermore, blood is 
dynamic and exerts hemodynamic (flow) forces on VTCs.  
In order to localize and bind to the vascular wall in blood flow, a VTC must 
navigate this complex fluid, evade immune clearance, and dock via receptor-ligand 
interactions at the wall, where it can act as an imaging/drug delivery agent. As mentioned 
earlier, vascular diseases are often associated with a chronic inflammatory response. When 
inflammation occurs, WBCs via the leukocyte adhesion cascade21 localize and bind to the 
vascular wall, in order to fight the infection. However, in the disease state, this process is 
chronic, which results in accumulation of cellular debris in the endothelium and 
progression of the disease. This process of leukocyte recruitment to the vascular wall 
during inflammation offers a model for designing VTCs to target the endothelium. Thus, a 
leukocyte-mimetic approach is applied here in designing VTCs, namely, by decorating 
VTCs with similar ligands as found on WBCs, or leukocytes. In particular, VTCs will 
mainly be targeted with sialyl-Lewisa (sLea), a tetrasaccharide carbohydrate which has high 
affinity for E-selectin. A similar version of this ligand (with lower affinity for E-selectin), 
sialyl-Lewisx is expressed on leukocytes, which facilitates their rolling on upregulated 
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selectins during inflammation22. It is known from the literature that RBCs impact the WBC 
recruitment process to the vascular wall, and thus it is expected that VTC adhesion would 
also be impacted by the complex nature of the blood environment23. Surprisingly, early 
work characterizing the adhesion of drug carriers in flow was often done in the absence of 
RBCs or at a sub-physiological level of RBCs, which thus limits how these results would 
translate to the whole blood environment in vivo24–27. In addition, limited studies probed 
the role of particle size on adhesion, and often the results were performed in non-
physiological environments or assumed particles were already close to the wall, neglecting 
the impact of navigating the complex flow environment28,29. Recent studies from our lab 
and others has focused on probing the role of RBCs, WBCs, flow profile, shear rate, as 
well as physiochemical properties of the VTCs on prescribing the adhesion efficiency of 
VTCs in human blood flow at physiologically relevant conditions30–35. Several key results 
have been observed but a paramount conclusion is that particle size plays an important role 
in the adhesion efficiency of VTCs in blood flow. Specfiically, microparticles vastly 
outperform the localization and adhesion of nanoparticles at a fixed concentration and 
ligand density30–32. Microparticles ~3 µm in diameter exhibit optimal adhesion at high 
shear rates (~1500 s-1) associated with cardiovascular diseases. Similar to WBCs, 
microparticles enjoy near wall excess effects from RBCs, resulting in better localization 
and adhesion than smaller nano-sized particles30,34.  The poor adhesion of nanoparticles in 
comparison is largely attributed to their ineffective transport to the vascular wall, and thus, 
the nanoparticles remain co-localized in the RBC core, limiting near wall excess effects 
and thus probability to reach and bind to the vascular wall in blood flow. Larger 
microparticles of 5 µm in diameter show better adhesion in some instances, but also more 
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sensitivity to negative WBC effects, shear forces, and overall too large a size for any 
intravenous application. Despite the perceived benefits of efficient microparticle adhesion, 
nanoparticles remain critical to the drug delivery field for their ease in navigating the 
microcirculation, evasion of systemic clearance, and overall better internalization 
efficiency. Thus, work in our lab has and continues to pursue options for improvement of 
nanoparticle adhesion for vascular targeting applications. Some avenues currently being 
explored include particle shape, density, and rigidity36–38.       
1.2.3 Translation of in vitro blood flow assays to biodegradable systems 
Undoubtedly, important knowledge regarding how hemodynamic properties of 
blood affect VTC adhesion was gained in the experimental studies from our lab and 
computational work by others. However, one limitation of the experimental studies from 
our lab was the use of polystyrene (PS) micro/nanoparticles, which are not viable for drug 
delivery applications and known to be toxic. Thus, the transition to biodegradable systems 
is a relevant next step in better understanding VTC design for vascular targeting 
applications. Initially, an experiment is performed which compares PS and PLGA 2 µm 
particles in whole blood and buffer flow (Fig. 1.1). As seen in the case of blood flow, 
PLGA adhesion is substantially reduced relative to PS. As mentioned earlier, blood is 
complex, composed of RBCs, WBCs, platelets, and protein-rich plasma, all of which may 
be responsible for the observed low adhesion of PLGA particles. Studies performed by  
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Figure 1.1 HUVEC adhesion of sLea-targeted (~800 sites/µm2) PS and PLGA 2 µm 
particles in human whole blood flow in a parallel plate flow chamber (PPFC) at 200 
s-1 for 5 mins at a concentration of 5 × 105 particles/mL. 
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Charoenphol et al. showed that the presence of RBCs increases adhesion density of 
micro/nanoparticles by providing a normal force on the particle in flow; thus, it would be  
expected that the effect exerted by RBCs on PS particles would be the same on PLGA 
VTCs, since RBCs are relatively inert and are not involved in any phagocytic mechanisms. 
Activated WBCs, on the other hand, have a higher propensity to interact with particles as 
studies from our lab have shown potential negative-adhesion events on VTCs due to 
WBCs. However, these negative-adhesion effects of WBCs were seen only in pulsatile 
flow environments and occurred at the point of adhesion due to physical effects, not 
molecular32. WBCs could potentially engulf particles in the bloodstream, but this is likely 
not the case since PS binding doesn’t show any such impact. Furthermore, the 
anticoagulant being employed is acid-citrate-dextrose (ACD) which chelates Ca2+ ions, 
thus limiting the probability of phagocytosis in general. Platelets are not expected to be 
involved in prescribing VTC adhesion based on previous work with PS spheres32. Thus, 
since plasma is the remaining major component in blood, it is the hypothesis and instinct 
that plasma is a player in this observed differential adhesion between PS and PLGA.  
However, this seems counterintuitive, since cellular adhesion is classically 
understood as a force-driven process governed by the strength of the receptor/ligand 
system, which is largely influenced by parameters such as particle size, local shear forces, 
and receptor/ligand densities25. Interestingly, these parameters are expected to be 
essentially constant between PS and PLGA in this experiment. Based on these initial 
results, the overarching aim of this thesis is to elucidate the potential role of plasma protein 
adsorption on the adhesion efficiency of VTCs in human blood flow, which remains 
relatively unknown. A vast array of literature, however, does discuss the relevance of 
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plasma protein adsorption in drug delivery processes such as cell signaling and clearance 
mechanisms.      
1.2.4 The plasma protein corona 
When a particle is exposed to blood plasma (e.g., intravenous injection), protein 
adsorption onto the particle surface occurs in seconds, forming what is typically referred 
to as the “plasma protein corona”39. The plasma protein corona is known to influence 
several key drug delivery processes and the literature has shown growing interest in 
understanding the corona’s significance to the field of targeted drug delivery40. Plasma is 
a highly complex protein solution, consisting of over 3,700 proteins, and thus the resulting 
plasma protein corona formed on nanoparticles comprises various types of proteins each 
with unique association/dissociation kinetics. The corona is classically understood via the 
Vroman effect, where highly abundant (low affinity) proteins such as albumin are replaced 
over time by scarce (high affinity) proteins; however, recent works have suggested this 
may not entirely explain the dynamics of corona formation40–42. The plasma protein corona 
varies significantly based on physicochemical properties of the nanoparticle, the 
physiological environment (e.g. plasma composition or type), and exposure time to the 
nanoparticle. The plasma protein corona alters the nanoparticle interface, resulting in a new 
biological identity of the nanoparticle. This new identity is often referred to as what the 
cell actually “sees” rather than the pristine nanoparticle surface. This nanoparticle 
biological identity determines various aspects of the physiological response, including 
toxicity, cell uptake, circulation time, biodistribution, and recently, implications in 
targeting. This section will provide details of factors governing plasma protein corona 
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formation followed by a discussion of the current understanding of the role of the plasma 
protein adsorption in drug delivery processes.  
1.2.4.1 Key parameters governing plasma protein corona formation 
Gessner et al. probed the impact of surface charge on plasma protein adsorption 
with hydrophobicity kept relatively constant across the differentially charged particles43. 
Overall, increasing the surface charge changed only the amount of protein in the corona, 
but did not change the specific types of proteins. Generally, increases in surface charge 
density were met with an increase in the amount of protein adsorption. The increase in 
protein adsorption amount over surface charge density is attributed mainly to Coulombic 
forces and less to van der Waal’s forces since the particles are of similar hydrophobicity. 
The results of this study contribute to understanding plasma protein adsorption at a 
fundamental level. The expectations, based on this investigation, are that a moderate 
surface charge gradient should leave the protein adsorption profile unaffected. In another 
study, cationic vesicles showed heavy binding of plasma proteins, another example of 
electrostatic interactions driving the extent of plasma protein adsorption36. Surface charge 
may also affect the conformation of the protein being adsorbed, as seen in the case of gold 
nanoparticles where charged ligands resulted in denaturing of the adsorbed protein44.  
Hydrophobicity can affect both the type and amount of proteins formed in the 
corona. In another study by Gessner et al., it was found that decreasing the surface 
hydrophobicity and keeping all other parameters constant, led to decreased protein 
adsorption as well as changes in the composition of the protein corona45. Surface 
hydrophobicity was observed to affect both the amount and composition of the protein 
corona; however, these results could also be influenced by the fact that different functional 
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groups were employed to achieve different hydrophobicity. In other reports, it has been 
observed that hydrophobic particles tend to adsorb more protein and also increase the 
extent of protein denaturation relative to hydrophilic or neutral particles39. The enhanced 
protein binding of hydrophobic particles is thought to be linked to the clustering of 
hydrophobic chains, which result in protein binding patches on the surface. In general, 
hydrophobic particles tend to have a greater affinity for albumin compared to hydrophilic 
ones39. Overall, similar to surface charge, increasing the particle hydrophobicity leads to 
greater protein adsorption, but hydrophobicity has also been observed to affect the type 
and, therefore, composition of the protein corona. 
Nanoparticle material type is another parameter which greatly affects the type of 
proteins adsorbed in the corona. A study by Deng et al. showed that different metal oxide 
nanoparticles of similar size and nearly equal zeta potential, adsorbed widely different 
plasma protein profiles46. In addition, differences in protein corona composition has been 
observed between single-walled carbon nanotubes and silica nanospheres47. A different 
study showed that the extent and type of adsorbed proteins on PLA, PCL, and 
polyanhydride poly(ethylene glycol) (PEG) particles varied significantly, potentially 
linked to differences in hydrophobicity48. 
It is known that the binding affinity of proteins depends on surface curvature, which 
varies with particle size. For instance, α-Synuclein binding affinity to lipid vesicles 
increased >15 fold on smaller particles relative to larger ones49. In the case of gold 
nanoparticles, increased protein adsorption has been observed on 30 nm versus 50 nm 
particles47. Over larger size ranges of nanoparticles from 70 – 700 nm, the amount of 
protein binding was shown to scale with available surface area50. Larger sized particles 
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have been observed to more likely cause protein denaturation upon adsorption. This was 
observed in the case of silica nanoparticles (20 versus 100 nm) where the larger 100 nm 
particles caused significant loss in α-helicity of adsorbed lysozyme protein51. In addition, 
thicker protein coronas have been observed with larger particles39. Overall, size can 
significantly affect the composition of the protein corona, particularly when the particle 
diameter is on the size scale of individual proteins50. 
One parameter unchanged in all the previous blood flow adhesion work with PS 
particles from our lab was the choice of anticoagulant. Experiments from our lab over the 
last decade have always employed acid-citrate-dextrose (ACD) as the working 
anticoagulant. The literature has shown that the type of anticoagulant affects properties of 
blood cells (particularly leukocyte uptake of particles)52, as well as the plasma protein 
composition53,54. Thus, the plasma composition in ACD versus heparinized (another 
common anticoagulant) blood is different. In addition, serum (contains no anticoagulant) 
also shows a unique protein composition compared to plasma. A major difference in 
protein composition between serum and plasma is the absence of fibrinogen and other 
clotting-related proteins54. A recent study has shown that the differences in plasma versus 
serum protein composition results in unique protein coronas formed on silica 
nanoparticles52. Thus, in addition to physicochemical properties of the nanoparticles, the 
plasma environment (i.e. type of/presence of anticoagulant) is an important parameter 
which could influence plasma-associated adhesion effects on drug carrier adhesion in blood 
flow. In addition, it is of great importance to probe the role of anticoagulant to provide a 
better  platform for translation of in vitro assays involving drug carriers interaction with 
blood to in vivo/clinical studies where plasma is not artificially anticoagulated.      
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1.2.4.2 Role of plasma protein corona in uptake, circulation time, and biodistribution 
Plasma protein adsorption onto nanoparticles causes opsonization, a process by 
which  any foreign material (e.g. nanoparticles) in the bloodstream are coated with 
primarily complement and immunoglobulin proteins which mark the foreign substance  for 
engulfment by the mononuclear phagocytic system (MPS) via Fc receptor interaction 
leading to clearance from the blood circulation55. In the case of developing targeted drug 
delivery systems, rapid clearance of particles from the bloodstream is a highly unwanted 
phenomenon as this potentially jeopardizes the impact of the particle for an application. 
Correlations between protein adsorption and clearance time have been studied by Chonn 
et al., where increased adsorption of beta 2-glycoprotein 1 resulted in shorter clearance 
times of negatively charged liposomes56. In another study, Schreier suggested the role of 
fibronectin protein in the clearance of liposomes57. In general, it has been observed that 
highly charged, hydrophobic particles lead to greater protein adsorption, which tends to 
result in higher and faster opsonization/uptake rates in plasma/serum than observed with 
neutral particles, which would be expected result in shorter clearance times58. In addition, 
particles with increasing hydrophobicity tend to adsorb more proteins which results in 
faster uptake rates58. Another study has probed the role of PEGylated nanoparticle size on 
macrophage uptake in the presence of serum and shown that larger particles (90 nm) were 
more efficient at being taken up than the smaller 15 nm particles59. Overall, the effect of 
serum/plasma protein adsorption on cellular uptake of nanoparticles significantly depend 
on the nanoparticle material type studied as well as physicochemical properties such as 
hydrophobicity, surface charge, material type, and particle size.    
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Given the tendency of particulate delivery systems to be cleared rapidly from 
circulation by phagocytosis due to plasma protein adsorption, widespread use of “stealth” 
mechanisms on particles designed to limit protein adsorption, increase in vivo circulation 
time and prevent interactions with the immune system have been explored. Potential 
avenues for limiting plasma protein adsorption often include the use of PEGylation48,55,60. 
PEGylation has long been known to limit protein adsorption by creating a hydrophilic layer 
and steric repulsion of proteins61,62. Thus, it is of interest to explore the possibility that PEG 
may eliminate, or at least, greatly reduce the negative plasma protein effects on VTCs. 
However, this may be a challenging because stealth effects are reduced when adding 
targeting ligands to PEGylated drug carriers. Properties of the targeting ligand and PEG 
density, molecular weight, and conformation can dramatically impact ligand affinity and 
VTC specificity, as well as corona presence and circulation time60,63–66. A debate remains 
whether PEGylated VTCs are truly free of the plasma effects in vivo48,60,67,68, and 
PEGylation may never completely limit protein adsorption on VTCs. In addition, 
prolonged circulation time via PEGylation, liver and spleen accumulation will still 
comprise a majority of the injected dose. Other hydrophilic coatings such as poloxamers 
have been applied to increase circulation lifetime and decrease macrophage recognition 
similar to PEG.  
Longer circulation times due to PEGylation of nanoparticles potentially offers 
better drug distribution throughout the body. In the case of quickly opsonized particles, 
rapid accumulation of nanoparticles in the liver and spleen may limit the potential for a 
nanoparticle to accumulate in the organ of interest. Like PEGylation, the adsorption of 
dysopsonin proteins like albumin and apolipoproteins may have stealth-like qualities as 
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adsorption of these proteins has been observed to decrease liver uptake and increase 
circulation time. Preferential adsorption of specific plasma proteins such as apolipoproteins 
has been observed to cause preferential uptake to brain endothelial cells, resulting in higher 
distribution to this organ69. In this instance, the protein corona may be highly beneficial if 
targeting the brain is of interest to the application. In another example, the preferential 
adsorption/covalent attachment of dysopsonin proteins such as albumin behave like 
PEGylated particles, evidenced by albumin helping nanoparticles to evade opsonization 
and uptake the immune system70. There also have been instances where receptor-mediated 
cell uptake is hindered due to protein adsorption, as observed by Salvati et al., where 
transferrin-targeted nanoparticles showed reduced uptake in serum via obstruction between 
the transferrin ligand/receptor system, suggesting that serum proteins crowd the surface 
and prevent the particle from interacting with its ligand68.  
Overall, the plasma protein corona impacts various processes such as particle 
circulation time, biodistribution, and cellular uptake. Furthermore, this is compounded by 
the fact that the formation of the plasma protein corona is heavily dependent on a host of 
physicochemical properties of nanoparticles, particularly surface charge, material 
(hydrophobicity), and size/curvature as well as the nature of the plasma (i.e. anticoagulant 
type or its absence). Although important knowledge has been gained by these studies 
characterizing the formation of the corona and its role in drug delivery relevant processes, 
the role of the protein corona on the adhesion efficiency of VTCs in human blood flow 
remains relatively unknown. Thus, the focus of this thesis is to elucidate the role that the 
plasma protein corona plays in the context of VTC adhesion in human blood flow via an 
in vitro parallel plate flow chamber. Specifically, this work will first probe PLGA-
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associated plasma adhesion effects for a variety of parameters classically known to impact 
VTC adhesion (e.g. shear rate, flow profile, ligand density) as well as physicochemical 
properties of the particle (size, ligand density, ligand type). Furthermore, this corona-
induced effect is found to be linked to the adsorption of large molecular weight proteins 
(i.e. immunoglobulins) and the impact of this protein class in causing these effects is 
explored in the following chapter. Another aspect of this thesis will evaluate the blood flow 
adhesion of other biodegradable materials besides PLGA, including PLA and PCL. In 
addition, a chapter will be dedicated to exploring the role of plasma anticoagulant (and its 
absence) on VTC adhesion efficiency since plasma is not a universal medium and recent 
work has shown that the choice of anticoagulant can have profound effects on the corona 
composition and thus may prescribe the corona-induced VTC adhesion effects. 
Understanding the role of anticoagulant is also important for translating/predicting VTC 
adhesion for eventual use in humans where anticoagulant is absent.   
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CHAPTER 2: MATERIALS AND METHODS 
 This chapter describes the procedures and materials used to complete the 
experimental in vitro flow assays described throughout this work. Detailed descriptions are 
provided to allow for reproduction of the results.  
2.1 Particles used for in vitro flow assays 
2.1.1 Biodegradable particles 
2.1.1.1 PLGA microparticle fabrication  
PLGA 5 µm particles were fabricated using a commonly employed oil-in-water 
solvent evaporation technique1,2. Briefly, 50:50 PLGA polymer with carboxylated end 
groups purchased from Evonik Industries (Parsippany, NJ) was dissolved in 20 mL of 
dichloromethane at ~2 mg/mL (oil phase) and injected into 90 mL polyvinyl alcohol (PVA) 
containing poly(ethylene-alt-maleic anhydride) (PEMA) for two hrs at 1800 rpm using a 
Lightnin’ mixer, allowing for evaporation of the dicholormethane and formation of solid 
particles. Differential centrifugation was employed to narrow the particle size 
polydispersity and reduce the amount of residual PVA. Particle solutions were then 
lyophilized overnight and the dry powder stored at -20°C until use.  
2.1.1.2 Purchased nanoparticles  
Fluorescent and blank carboxylated 500 nm and 2 µm PLGA particles as well as 
500 nm polylactic acid (PLA) and polycaprolactone (PCL) carboxylated particles were 
purchased from Phosphorex, Inc. (Hopkinton, MA).  
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2.1.2 Non-biodegradable particles 
Green fluorescent carboxylated Si (Cat# 140574-10) and PS 500 nm particles were 
purchased from Corpuscular (Cold Spring, NY) and Polysciences, Inc. (Warrington, PA) 
as a comparison with the biodegradable materials. PS carboxylated 2 µm particles were 
purchased from Bangs Laboratories, Inc.  
2.2 Particle characterization 
2.2.1 Concentration  
Particle concentration was measured using a hemacytometer (Hausser-Scientific). 
Blank PLGA, PLA, and PCL 500 nm particles were diluted and stained with biotin-PE to 
allow visualization of particles prior to manual counting.  
2.2.2 DLS sizing 
VTC size was measured by dynamic light scattering (DLS) using a Malvern Zetasizer 
instrument. Carboxylated stocks were dispersed in PBS++, with 1% bovine serum albumin 
(BSA) and then washed with 50 mM PBS prior to making the DLS measurement. 
Carboxylated biodegradable PLGA, PLA, and PCL particles were soaked in 50 mM MES 
at pH 7 (for PCL, pH ~5) for > 20 hr prior to DLS measurement which corresponds to the 
time required for NeutrAvidin conjugation to these particles. Particle concentrations tested 
for DLS measurements ranged from 108-109 #particles/mL as this concentration range was 
observed to yield the most reliable results. 
2.2.3 Zeta potential 
Zeta potential measurements were obtained using the Malvern Zetasizer 
instrument. Concentration of particles in deionized water varied from 0.65 to 2.5 × 107 
#particles/mL which is similar to the concentrations used in the flow assays. Zeta potential 
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was measured for particles soaked in buffer, plasma, and serum with subsequent washing 
in deionized water prior to the measurement.  
2.2.4 Surface ligand conjugation 
2.2.4.1 NeutrAvidin, albumin conjugation 
Particle stocks were first conjugated with NeutrAvidin via covalent carbodiimide 
chemistry followed by linkage to biotinylated sialyl-Lewisa (sLea) (Glycotech Corporation) 
or anti-ICAM-1 (R&D Systems). The coupling of NeutrAvidin has been described 
elsewhere3. Briefly, an approximate particle surface area of 9.1 × 109 µm2/mL of 
conjugation volume was used. The conjugation volume consisted of equal parts 
NeutrAvidin (5 mg/mL) and N-Ethyl-N′-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDAC) (Sigma) (75 mg/mL) dissolved in 50 mM 2-(N-
morpholino)ethanesulfonic acid (MES) buffer. VTCs were first incubated with 5 mg/mL 
NeutrAvidin for 15 min, followed by addition of an equal volume of EDAC at 75 mg/mL. 
1 M sodium hydroxide (NaOH) was added (~47 µL/mL conjugation volume) to pH the 
solution to ~7.4 and allowed to rotate on an end-to-end rotator for ~20 hr. For PCL VTCs, 
no NaOH was added as this caused precipitation during the overnight conjugation process, 
and thus the reaction was carried out at pH ~5. Following the 20-hr incubation step, ~7.5 
mg glycine/mL was added to the conjugation solution stop the crosslinking reaction and 
allowed to incubate for 30 min. Conjugated VTCs were washed and re-suspended in 1 mL 
of 50 mM phosphate buffered saline (PBS). 
For some assays, human serum albumin (HSA) was covalently linked to the surface 
of PLGA particles by adding in a 4:1 ratio with NeutrAvidin with a final concentration of 
10 mg/mL HSA and 2.5 mg/mL NeutrAvidin.  
28 
 
2.2.4.2 sLea, anti-ICAM-1, and polyethylene glycol (PEG) conjugation 
 Attachment of targeting ligands was performed by suspending NeutrAvidin coated 
particles in 100 µL of biotinylated sLea or anti-ICAM-1 (dissolved in PBS with calcium 
and magnesium (PBS++) with 1% BSA) at concentrations ranging from 0.4 to 10 µg/mL. 
Surface area to volume ratio of the various VTCs was varied to achieve the desired ligand 
site density. NeutrAvidin-coated particles were allowed to rotate in the targeting ligand 
solutions for 45 mins, and then washed 3 times with PBS++ 1% BSA buffer and suspended 
in a final volume of 1 mL.  
 For PEGylated PLGA particle assays, PLGA particles were grafted with PEG 
chains prior to targeting ligand conjugation, as previously described4. Briefly, amine-PEG 
(5 kDa)-biotin was covalently linked to the PLGA surface in the same manner as described 
with NeutrAvidin. For ligand conjugation onto the PEG, biotinylated sLea was premixed 
with 20 µg/mL of NeutrAvidin at an equal volume ratio for 20 mins. This premixed solution 
was then allowed to incubate for 45 mins with the PEGylated PLGA particles.   
2.2.5 sLea, anti-ICAM-1, PEG and albumin density quantification 
sLea ligand density was quantified via flow cytometry using an Attune flow 
cytometer (Applied Biosystems) as described elsewhere3. For quantifying sLea density, 
0.5-1 × 106 particles were incubated for 20 mins in a 1:10 solution (100 µL volume) of anti-
CLA-PE (Miltenyi Biotec). Following the incubation step, VTCs were washed 3 times with 
PBS++ with 1% BSA buffer and suspended in a final volume of 1 mL. Rat-IgM-PE (Fisher 
Scientific) was used as the isotype control. Quantification of the number of ligand sites on 
the particle surface was achieved via use of Quantum R-PE MESF calibration beads (Bangs 
Laboratories).  
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Biotinylated anti-ICAM-1 was quantified in a similar manner. The dye used was 
goat-anti-mouse-IgG-FITC (Jackson ImmunoResearch), and the isotype control, goat IgG 
FITC (Jackson ImmunoResearch). Anti-CLA-PE and goat anti-mouse IgG FITC were used 
to quantify sLea and anti-ICAM-1 density on VTCs, respectively. To assist in gating and 
visualization of non-fluorescent 500 nm particles during flow cytometry, sLea and anti-
ICAM-1 coated particles were stained with biotin-FITC or biotin-PE prior to sample 
testing.  
The PEG density on PLGA particles was quantified via staining surface PEG-biotin 
molecules with avidin-FITC purchased from Thermo Scientific (Waltham, MA). This 
protocol is described elsewhere4, and similar to anti-ICAM-1 quantification, the 
Quantum™ FITC-5 MESF (Premix) beads were used.  
Lastly, HSA was quantified on the particle surface using a human albumin FITC-
conjugated antibody purchased from antibodies-online Inc. (Atlanta, GA).  
2.3 HUVEC cell culture 
HUVECs were obtained via a commonly used collagenase perfusion method5. 
Umbilical cords were generously donated by the U of M hospital under a Medical School 
Internal Review Board (IRB-MED) approved human tissue transfer protocol 
(HUM00026898). The protocol is exempt from informed consent per federal exemption 
category #4 of the 45 CFR 46.101.(b). HUVECs isolated from the umbilical cords were 
pooled and grown in tissue culture using T-75 flasks pre-coated with 0.2 wt%/v gelatin. 
Preparation of HUVEC coated coverslips for flow chamber assays is described 
elsewhere5,6. HUVEC monolayers were activated with 1 ng mL-1 interleukin 1-beta (IL1-
β) for 4 hrs prior to performing the flow experiment.  
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2.4 Blood preparation 
2.4.1 Whole blood 
ACD or heparinized whole blood was prepared by drawing blood from healthy 
human donors into a syringe containing acid-citrate dextrose (ACD) or heparin. 
Anticoagulant solutions were added at a ratio of 0.14 mL/mL blood.  
2.4.2 Plasma 
For preparation of plasma, whole blood with anticoagulant (ACD or heparin) was 
centrifuged at 2250g for 20 min, typically at 4°C and the supernatant collected. An 
additional spin at 6797g for 5 min was used to ensure any residual cells were removed. 
2.4.3 Serum 
For preparing serum, blood without any additive was allowed to sit upright in a 50 
mL conical tube for ~2 hr, and then centrifuged at 2000g for 10 min at 4°C. An additional 
5-min spin at 6797g was performed to ensure any residual cells were removed.  
2.4.4 Immunoglobulin/albumin depleted plasma and serum 
Plasma depletion of immunoglobulins and albumin using the PureProteome™ 
Human Albumin/Immunoglobulin Depletion Kit (EMD Millipore). Specifically, 25 µL of 
human plasma or serum was diluted with 1X PBS (1:4) to a total volume of 100 µL. This 
25% plasma solution was then incubated with 900 µL of the depletion beads and incubated 
for 1 hr at room temperature on an end-to-end rotator. Solution was centrifuged and the 
supernatant contained the immunoglobulin/albumin depleted plasma. Commerically 
obtained human serum albumin was added for depleted Igs assays.  
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2.4.5 IgG depletion and isolation 
 To prepare IgG-depleted plasma, a Protein A antibody purification kit from Sigma-
Aldrich (St. Louis, MO) was used. A detailed protocol regarding use of this product 
provided in the technical bulletin was followed with slight modifications. Briefly, ~2 mL 
of plasma was mixed with 4 mL of PBS and filtered with a 0.45 µm filter. The desalting 
cartridge is equilibrated with HEPES buffer and the Protein A cartridge washed with 
regeneration buffer. Then, the Protein A cartridge is equilibrated with the binding buffer 
used to dilute the plasma. The plasma/binding buffer mixture is passed through the Protein 
A cartridge which binds IgG. The outlet contains IgG depleted plasma. Bound IgG was 
isolated using the provided elution buffer and concentration via Amicon® Ultra-4 
centrifugal filters. Protein concentration was measured via NanoDrop 2000c.   
2.4.6 IgA depletion and isolation 
 To prepare IgA-depleted plasma, an IgA depletion column was purchased from 
GenWay Biotech, Inc (San Diego, CA). 40 µL of plasma was diluted with tris buffered 
saline (TBS) to a total volume of 400 µL and incubated with anti-IgA beads in a spin 
column for 15 mins and the resulting filtrate (IgA-depleted plasma) collected. Isolation of 
bound IgA was performed by incubation for 2-3 mins with 0.1 M glycine (pH=2.5). IgA 
protein was then concentrated using the Amicon® Ultra-4 centrifugal filters. Protein 
concentration was measured via NanoDrop 2000c.  
2.4.7 RBCs-in-Buffer 
RBCs-in-Buffer was prepared by adding 0.14 mL of 6 wt%/v dextran/ mL whole 
blood and allowing to sit upright for ~2 hr. After this process, RBCs were collected and 
washed via centrifugation.  
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2.4.8 Reconstituted blood: RBCs-in-VB, RBCs-in-Serum  
Suspension of washed RBCs in viscous buffer (RBCs-in-VB) was used as the 
control assay for adhesion in plasma-containing whole blood/RBCs-in-Serum flow. VB 
refers to a buffer solution with viscosity matching that of human plasma and consisted of 
PBS++ with 1 wt% BSA and 1.4 wt% dextran. To prepare reconstituted blood assays (e.g. 
RBCs-in-VB, RBCs-in-Serum), RBCs from ACD WB were washed 3 times with PBS(--) 
via centrifugation at 1000g for 30 mins. A final wash was performed at 2250g for 20 min, 
and VB or serum was added to the RBC pellet to achieve a matching hematocrit to that 
obtained with ACD whole blood.  
2.4.9 Hematocrit  
To determine the hematocrit, whole blood was centrifuged at 2250g for 20 min, and 
the volume of the RBC pellet/total volume added was taken as the hematocrit value.  
2.5 Parallel plate flow chamber assays 
2.5.1 Laminar flow assays 
Flow adhesion assays were performed using a Nikon TE 2000-S inverted 
microscope fitted with a digital camera. The microscope incubator was heated to ~37°C 
prior to the experiment. Circular parallel plate flow chambers (Glycotech Corporation) 
containing a straight rectangular channel and rubber gasket were used in these assays, as 
described elsewhere3,5–7. Briefly, for each trial, an activated coverslip containing a 
monolayer of HUVEC was vacuum-sealed to the bottom of the flow chamber deck. The 
outlet of the flow chamber is connected to a syringe pump, which controls the flow rate. 
VTCs were first mixed with blood, RBCs-in-Serum, or RBCs-in-VB at a concentration of 
1 × 106 particles mL-1. Next, the VTC-blood mixture was added to a syringe connected to 
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the flow chamber inlet. The duration of each flow assay was 5 min at a shear rate of 200 
or 500 s-1. After the flow experiment, images of bound VTCs on the HUVEC monolayer 
were collected along the channel width at a fixed position from the channel entrance. The 
amount of bound VTCs were counted and the adhesion density obtained.  
 For the biodegradable VTCs (PLGA, PLA, PCL), non-fluorescent particles were 
used to limit any effect of a fluorescent dye on VTC-protein interaction. These particles 
were exposed to plasma, serum, or VB (300 µL) for 5 min to set the corona based on PLGA, 
PLA, or PCL material interaction. After the plasma/serum/VB incubation, particles were 
labeled with biotin-PE antibody (added 3 µL of 1 mg mL-1 biotin-PE solution) and the flow 
assay immediately performed. For anticoagulant-free (ACF) WB assays, biotin-PE stained 
biodegradable VTCs were stored in flow buffer or soaked in VB prior to the assay. 
2.5.2 Pulsatile flow assays 
In addition, some assays were performed using an oscillating pulsatile flow profile, 
which maintained an average shear of 0 s-1, pulsing back and forth with a peak shear rate 
of 1000 s-1 for a total of 15 min.   
2.5.3 Plasma depleted soaking assays 
In the case of depleted plasma assays, 5 µm particles were soaked for 1 hr in PBS 
1X, plasma, or depleted plasma prior to performing the flow assay in buffer. For the 500 
nm particles, RBCs-in-VB (38% hematocrit) was used as the flow medium.  
2.6 SDS-PAGE 
SDS-PAGE was performed using 4-20% precast gels from Bio-Rad laboratories. 
sLea VTCs were exposed to plasma (ACD or heparinized), serum or VB similar to 
preparation for flow assay. The total exposure time of VTCs to the different media—
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anticoagulated plasma, serum, or VB was ~10 min, including a 5-min soaking step and 5- 
min centrifugation spin (6797g) to collect the soaked particles and remove the media 
supernatant. VTCs were then washed 3 times with 50 mM PBS, and suspended in a final 
volume of 50 µL of detergent solution (0.06 M Tris-HCl, 1% SDS, 10% glycerol, lane 
marker tracking dye, pH 6.8) obtained from a SDS-PAGE Sample Prep Kit (Pierce). The 
VTC solution was then heated to 95°C for 5 mins using a thermocycler to remove the 
corona proteins and then centrifuged for 5 min to collect the protein supernatant. For each 
condition, 15 µL of the protein supernatant was loaded into an individual lane on the gel 
and ran for ~25 min at 200 V. The molecular weight standard was obtained from Bio-Rad 
Laboratories, Precision Plus Dual Color Protein Standards.  
2.7 ELISA 
 Sandwich ELISA was employed for measurement of human plasma IgG, IgA1, and 
IgM concentrations. Clear, high-binding 96-well plates were coated with the appropriate 
antibody at 1 µg/mL overnight (50 µL/well). To capture IgG, IgA1, and IgM, goat anti-
human IgG-unlabeled, Goat anti-human IgA-unlabeled, and goat anti-human IgM-
unlabeled were used as the coating antibodies and purchased from Southern Biotech 
(Birmingham, AL). Plates were washed with PBS 1X + 0.05% Tween-20 and blocked for 
~1 hr with 10% FBS (200 µL/well). Plasma was diluted 1:1e5 – 1:1e8 as this provided a 
linear working range for the different immunoglobulin proteins. Quantification was 
achieved by comparison with a standard curve consisting of commercially obtained IgG, 
IgA, and IgM solutions. For assay detection, horseradish peroxidase (HRP) conjugated 
antibodies were incubated with samples at ~0.1-0.8 µg/mL for 1 hr, depending on the 
specific antibody type. The following detection antibodies (Southern Biotech) at 100 
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µL/well were used in this assays: mouse anti-human IgG Fc-HRP (Clone: H2), mouse anti-
human IgA1-HRP (Clone: B3506B4), and mouse anti-human IgM-HRP (Clone: SA-DA4). 
After washing, 50 µL/well of TMB substrate was added, and after ~5 min, 1N H2SO4 was 
added to stop the reaction. Absorbance measurements were taken at 450 nm with 570 nm 
as the background.  
2.8 Mass spectrometry 
 Selected gel bands were digested using trypsin and analyzed using LC/MS/MS on 
a ThermoFisher Velos Orbitrap mass spectrometer. The NCBI protein database allowed 
for identification of product ion data using the Mascot and X-Tandem Search engines. 
Output files from Mascot were parsed into Scaffold software to confirm the correct 
identification of proteins.  
2.9 Data analysis 
Data was analyzed using Prism. Data in figures was plotted with standard error and 
comparisons between adhesion assays were performed using 1 way ANOVA with Tukey 
post-test and confidence interval of 99% (α=0.01).  
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specific manner. PLoS One 9, e107408 (2014). 
 
ABSTRACT 
 The nanoscale plasma protein interaction with intravenously injected particulate 
carrier systems is known to modulate their organ distribution and clearance from the 
bloodstream. However, the role of this plasma protein interaction in prescribing the 
adhesion of carriers to the vascular wall remains relatively unknown. Here, we show that 
the adhesion of vascular-targeted poly(lactide-co-glycolic-acid) (PLGA) spheres to 
endothelial cells is significantly inhibited in human blood flow, with up to 90% reduction 
in adhesion observed relative to adhesion in simple buffer flow, and the extent of this 
reduction depends on  blood flow magnitude and pattern. In addition, this reduced PLGA 
adhesion in blood flow is linked to the adsorption of certain high molecular weight plasma 
proteins on PLGA and is donor-specific, where large reductions in particle adhesion in 
blood flow (80% relative to buffer) is seen with 60% of unique donor bloods while others 
exhibit moderate to no reductions. Furthermore, the extent of the reduced adhesion of 
PLGA is a function of ligand density and plasma exposure time. The observed plasma 
protein effect on PLGA is likely due to material characteristics since the effect is not 
replicated with polystyrene or silica spheres, which effectively adhere to the endothelium 
at a higher level in blood over buffer flow. Overall, understanding how distinct plasma 
38 
 
proteins modulate the vascular wall interaction of vascular-targeted carriers of different 
material characteristics would allow for the design of highly functional delivery vehicles 
for the treatment of many serious human diseases. 
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3.1 Introduction 
 
 Injectable vascular-targeted carrier (VTC) systems hold great promise for the 
effective diagnosis and treatment of many human diseases by non-invasively providing 
localized delivery of imaging agents or potent therapeutics. However, to date, only a few 
VTCs have been effectively translated into the clinic1. A potential source for the limited 
utility of VTCs could be linked to the assumption that drug carriers will efficiently localize 
and bind to the vascular endothelium in blood flow irrespective of size, shape, and material 
characteristics. Recent studies from our lab and others have shown that particle size, shape, 
and interaction with blood cells prescribe successful adhesion of VTCs in blood flow2–4. 
However, the experimental studies probing the impact of red blood cells (RBCs) and forces 
on VTC adhesion have been largely been limited to non-degradable, toxic polystyrene (PS) 
particles. Thus, it is a natural step to consider the adhesion of biodegradable VTCs, such 
as poly(lactic-co-glycolic-acid) (PLGA), as they are more representative of drug carriers 
for clinical application. 
 A preliminary experiment testing the adhesion of PLGA and PS particles (Chapter 
1, Figure 1.1) revealed that the adhesion of PLGA particles is substantially reduced in 
human blood flow. It is the hypothesis that plasma is involved in the reduced adhesion 
effect of PLGA, since the main component of blood, RBCs, are mainly inert and would 
likely interact in a similar way with both PLGA and PS particles and are known to have a 
positive effect on adhesion in the experimental setting in Figure 1.1. In addition, previous 
work with PS VTCs revealed insignificant effects on adhesion due to white blood cells 
(WBCs) and platelets. Furthermore, WBC processes such as phagocytosis which, may 
reduce availability of particles, are largely limited in these assays due to the anticoagulant 
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employed here (acid-citrate-dextrose (ACD)) and the duration of the experiments (5-15 
min).  
Interestingly, the majority of published literature on plasma protein interaction with 
targeted drug carriers has focused on opsonization5,6, which leads to particle recognition 
and clearance from the bloodstream by macrophages. Only recently have a few studies 
reported that the plasma protein corona (the layer(s) of surface bound protein) formed on 
nanoparticles (NPs) can interfere with the ligand-receptor interaction, suggesting such 
impacts highly depend on the targeted cell or protein7–9. However, it is known that the 
plasma protein corona which rapidly forms on drug carrier surfaces after exposure to blood 
depends on a variety of physicochemical properties, including the particle material type10, 
which can result in distinct cellular interactions. While these studies undoubtedly provide 
useful insight into the range of possible impacts of the corona on carrier targeting, the 
impact of plasma protein adsorption with regard to particle material composition has 
largely been overlooked. Moreover, these analyses of corona effects on targeting have been 
conducted with simple animal sera or culture media in static assays that may not encompass 
the complexity of the realistic human blood flow environment in which VTCs must 
function, i.e., presence of hydrodynamic forces and blood cell interactions.  
The preliminary experiment in Figure 1.1 suggests that plasma protein adsorption 
could play a critical role in the adhesion of PLGA carriers in human blood flow. In this 
work, the potential role of plasma protein adsorption on the adhesion efficiency of PLGA 
VTCs in human blood flow is explored. Specifically, PLGA particle adhesion to HUVEC 
in human blood flow is measured via an in vitro parallel plate flow chamber (PPFC) for a 
variety of carrier (e.g., size, ligand density), flow (e.g., shear rate, profile), and blood (i.e., 
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donor) properties, as these variables may regulate any potential plasma-associated effect 
since protein corona formation is dependent on many types of parameters. 
3.2 Results 
3.2.1 Evaluation of PLGA adhesion in a variety of blood flow media 
The objective of this study is to elucidate the potential role of the plasma protein 
corona on the adhesion of PLGA VTCs to HUVEC in blood flow for a variety of particle, 
flow, and blood properties. First, the adhesion of 5 µm, 2 µm, and 500 nm PLGA spheres 
is tested under laminar flow in a PPFC at a shear rate of 200 s-1 for a variety of blood flow 
media (Figure 3.1A) to tease out the effect of individual components of blood on PLGA 
adhesion and determine if plasma is the source for the low adhesion in blood. Based on 
dynamic light scattering (DLS) measurements, the actual average sizes for the 500 nm, 2 
µm and 5 µm particles used here were 330 nm, 1.4 µm and 4.6 µm respectively (Table 3.1). 
Table 3.1 Particle size measurements via dynamic light scattering (DLS) 
Particle diameter (µm)  Material Dispersant Z-average (µm) 
PDI 
(
𝝈𝟐
?̅?𝟐
) 
0.490  PLGA (YG) PBS++ 0.334 0.232 
0.534 PS (G) PBS++ 0.567 0.032 
2.35 PLGA PBS++ 1.407 0.496 
2.1 PS PBS++ 2.219 0.150 
5 PLGA PBS++ 4.586 0.243 
5 PS PBS++ 4.946 0.047 
  
On average, the adhesion of the 4.6 µm PLGA microspheres to activated HUVEC 
is 93% lower in low shear human whole blood flow relative to the adhesion of the same 
particles in a simple buffer flow system (Figure 3.1B). This discrepancy in particle 
adhesion between simple buffer versus blood flow is not solely explained by the viscosity 
difference between the two different mediums since the adhesion level observed for the 
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spheres in blood is still 89% lower than their adhesion in the viscous buffer flow. On 
average, the HUVEC adhesion of 1.4 µm sLea-PLGA spheres in blood flow is 83% lower 
relative to the adhesion of the same particles in simple buffer flow (Figure 3.1C). Again, 
the adhesion level of the 1.4 µm spheres in blood is still 73% lower than their adhesion 
level in the viscous buffer. For the 330 nm sLea-PLGA spheres, particle adhesion in low 
shear laminar blood flow is 83% less than the observed adhesion in simple buffer, while 
this same blood adhesion is 85% less than the adhesion of nanospheres in high viscosity 
buffer (Figure 3.1D). To determine whether the reduced PLGA adhesion in human blood 
flow is due to particle-blood cell interactions or particle-plasma protein interactions, the 
HUVEC adhesion of sLea-PLGA spheres was evaluated in plasma (cell-free) flows. 
Overall, PLGA spheres also exhibit significantly lower adhesion to activated HUVECs in 
plasma flows relative to adhesion in viscous buffer flows, with 92%, 80%, and 63% 
reduction in adhesion in plasma flow for the 330 nm, 1.4 µm, and 5 µm spheres, 
respectively. To further confirm the role of plasma proteins, experiments were conducted 
with particles in laminar flow of human RBCs washed and then suspended in buffer (RBC-
in-Buffer). The adhesion levels of the 330 nm and 1.4 µm spheres in RBC-in-Buffer flow 
are 176% and 55% higher than the values observed in simple buffer flow, respectively. As 
such, the levels of reduction in the adhesion of these particles in whole blood (essentially 
RBCs-in-Plasma) are 94% and 89% lower compared to the observed adhesion in their 
respective RBC-in-buffer assays. Visualization of particle stability (spheres in solution 
placed on a glass coverslip) via phase or fluorescent imaging shows all particles to exhibit 
uniform dispersity in buffer and plasma (Figure 3.2), suggesting that particle aggregation  
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Figure 3.1 Summary of the adhesion of PLGA spheres from flow of buffer, plasma, and 
blood to an activated endothelial cell monolayer. (A) A depiction of particle 
margination in buffer, plasma, and blood flow. Binding density after 5 min of flow 
for (B) 4.6 μm, (C) 1.4 μm and (D) 330 nm sLea-coated PLGA particles to activated 
HUVEC monolayer from laminar buffer, plasma, or whole blood at 200 s-1. Particle 
concentration = 5 × 105 particles/mL for 4.6 and 1.4 μm data and 1 × 106 
particles/mL for the 330 nm particles. sLea density = 1,700 +/- 100 sites/μm2 (SEM) 
surface for 4.6 μm, 1500 +/- 100 sites/μm2 (SEM) for 1.4 μm and 9,000 +/- 400 
sites/μm2 (SEM) for 330 nm particles. N = 3 distinct donors (donors A, B, and C).  
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which has been previously reported for particles (e.g., iron oxide nanoparticles) upon 
exposure to cell culture media or plasma11–13 is likely not responsible for the observed 
reduced adhesion of PLGA spheres to HUVECs in the whole blood/plasma flow 
environment. In addition, sample images of the HUVEC monolayer in the PPFC after 
perfusion of PLGA spheres in RBCs-in-buffer, whole blood, and plasma flow are shown 
in Figure 3.3. Several bound PLGA particles are easily visualized on the monolayer for the 
assays with the particles in RBC-in-buffer (Figure 3.3A) whereas minimal particles are 
found on the monolayers perfused with particles in blood (Figure 3.3B) or plasma (Figure 
3.3C). The HUVEC monolayers exposed to RBC-in-buffer and whole blood flows were 
visually similar and the monolayer integrity is shown to be intact with binding of WBCs 
visible in both images. The image of the monolayer exposed to particles in cell-free plasma 
also shows essentially no particle binding and a robust cell monolayer remains even after 
exposure to human plasma.  
3.2.2 Evaluation of human blood donor on PLGA adhesion 
The adhesion of 4.6 µm sLea-PLGA spheres in low shear laminar flows of plasma 
was analyzed for several individual donors to determine any variation in particle adhesion 
that may be linked to differences in the plasma protein composition of each donor. The 4.6 
µm PLGA sphere size is highlighted in the individual donor assays since the magnitude of 
the reduction in particle adhesion in plasma flow relative to buffer flow is smaller for this 
particle size. As shown in Figure 3.4A, the 4.6 µm PLGA spheres in flow of plasma from 
∼42% of the donors evaluated show an average of 72 ±15 % (SEM) reduction in adhesion 
relative to the adhesion in the viscous buffer control (donors A, C, H, J, and N are referred 
to as “low-HUVEC binding donors” hereafter), whereas there was no evidence of reduced  
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Figure 3.2 Phase and fluorescence images of small PLGA spheres. Phase image of 1.4 μm 
PLGA particles in PBS+/+ (A) and plasma (B), and fluorescence image of 330 nm 
PLGA in PBS+/+ (C) and plasma (D).  Particles were added to the desired medium 
for 5 min in static after which a small amount of the particle solution is placed on a 
coverslip for imaging.  All images shown were taken at a 40X magnification. Scale 
bar = 10 μm. 
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Figure 3.3 Sample images of activated HUVEC monolayers exposed to PLGA under 
different flow types. Phase image of 1.4 μm sLea-coated PLGA spheres bound to 
IL1-β-activated HUVEC monolayer after 5 min of flow of particles in (A) RBC-in-
Buffer, (B) whole blood, and (C) plasma at 200 s-1. Image taken at 20X 
magnification. sLea density =  1500 +/- 100 sites/μm2 (SEM). Particle concentration 
= 5e5 particles/mL. Scale bar = 20 μm. 
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adhesion for the 4.6 µm PLGA spheres in plasma flow assays with another 50% of donors 
(donors D, E, I, K, L, and R are referred to as “high-HUVEC binding donors” hereafter). 
Specifically, PLGA adhesion in plasma flow of this subset of high HUVEC binding 
donors occurred at a similar level to the adhesion in viscous buffer flow. PLGA adhesion 
in the plasma flow of one donor B displays an intermediate level of reduction (∼45%) 
relative to adhesion in viscous buffer. Interestingly, the PLGA adhesion levels between 
plasma and whole blood assays for the low binding donor bloods are not statistically 
significant, whereas the opposite is the case for the adhesion of the spheres in the whole 
blood versus plasma flow assays for most of the high-binding donor bloods. To determine 
whether the donor effect observed for the 4.6 µm PLGA particles also exists for the smaller 
sized particles, the flow adhesion of 330 nm spheres was evaluated in a subset of the same 
donors used for the 4.6 µm particle adhesion assays. 
Interestingly, while there is minimal impact of plasma proteins seen in the adhesion 
of the 4.6 µm PLGA particles in the plasma flow assays with high HUVEC binding donors 
compared to viscous buffer, the plasma adhesion of the PLGA nanospheres is statistically 
lower in both the low and high HUVEC binding donors than their adhesion in viscous 
buffer flow (Figure 3.4B). However, nanospheres do exhibit a smaller reduction in their 
adhesion levels in assays with high HUVEC binding donor plasmas relative to buffer 
versus the reduction levels observed in assays with low HUVEC binding donor plasmas 
(donors D, L versus A, C). The adhesion of the nanospheres in whole blood flow of the 
high donors is not statistically different from adhesion in viscous buffer. We also evaluated 
the individual donor plasma flow adhesion of 4.6 µm PLGA spheres that were prepared  
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Figure 3.4 Particle adhesion to activated HUVEC in laminar flow of individual donor 
plasma and blood at 200 s-1. Adhesion of (A) 4.6 μm and (B) 330 nm PLGA spheres 
at high sLea density and (C) 4.6 μm spheres at low and high sLea density.  Viscous 
buffer controls are shown on the left side of the graph. sLea density = 1,800 +/- 100 
sites/μm2 (SEM) in (A), 9,000 +/- 300 sites/μm2 (SEM) in (B) and 130+/-10 and 
1800 +/- 100 sites/μm2 (SEM) in (C). Adhesion data collected after 5 min of flow 
time. Particle concentration = 5 × 105 particles/mL for 4.6 μm data and 1 × 106 
particles/mL for the 330 nm particles. N = 2 distinct assays for each donor. ns = 
Not significant at 99% confidence interval.  
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with a low sLea density (130 ± 10 sites/µm2), which is anticipated to increase the available 
space for protein to adsorb onto the particle. The low density sLea particles exhibit 
significantly lower adhesion in plasma flow of 70% of donors relative to adhesion in 
viscous buffer flow (Figure 3.4C) compared to the plasma flow assays with high 
sLea density particles where only 50% of donor bloods resulted in a comparable level of 
reduction in PLGA adhesion relative to viscous buffer. 
3.2.3 Evaluation of the effect of flow magnitude and profile on PLGA blood flow 
adhesion 
 Adhesion of 330 nm and 1.4 µm PLGA spheres were also evaluated in assays with 
a high shear (500 s−1) laminar flow and in a pulsatile flow with alternating forward/reverse 
flow at high shear (1000 s−1) and a net forward flow14. As shown in Figure 3.5A, the levels 
of reduction in the adhesion of 1.4 µm spheres in high shear laminar plasma and whole 
blood flows relative to high shear laminar buffer flow (∼80% and ∼90%, respectively) are 
similar to the level of reduction in adhesion observed in plasma and whole blood flows 
versus buffer flow for the low shear laminar assays. However, when adhesion in high shear 
laminar whole blood flow is compared to that in high shear laminar RBC-in-buffer flow, a 
slightly higher reduction in adhesion is observed for the 1.4 µm spheres at high shear 
compared to low shear. Specifically, there is a 95% reduction in blood flow adhesion 
relative to adhesion in RBC-in-buffer flow at high shear compared to the aforementioned 
89% reduction for the same comparison at low shear. In pulsatile flow, the overall adhesion 
of the 1.4 µm PLGA spheres in blood flow is minimal, with a 95% and 99% reduction in 
adhesion observed relative to adhesion in buffer and RBC-in-buffer flows, respectively 
(Figure 3.5B). For the 330 nm spheres, the reductions in particle binding in whole blood  
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Figure 3.5 Average adhesion of 1.4 μm and 330 nm sLea–coated PLGA spheres to 
activated HUVEC in buffer, viscous buffer, plasma, blood, and RBC-in-buffer 
flows. Panels (A) and (B) shows the adhesion of 1.4 μm spheres in laminar shear at 
500 s-1 and pulsatile flow with peak shear at 1000 s-1, respectively.  Panels (C) and 
(D) show the adhesion of 330 nm PLGA spheres in laminar shear at 500 s-1 and 
pulsatile flow with peak shear at 1000 s-1, respectively. sLea density = 1700 +/- 100 
sites/μm2 (SEM) for 1.4 μm spheres and  7000 +/- 300 sites/μm2 (SEM) for 330 nm 
spheres. Particle concentration = 5 × 105 particles/mL for 1.4 μm data and 1 × 106 
particles/mL for the 330 nm particles.  Laminar flow was run for 5 min and pulsatile 
flow for 15 min.  N = 3 distinct trials (donors) for the plasma and blood flow assays. 
ns = Not significant at 99% confidence interval.  
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flow at higher laminar shear and in pulsatile flow relative to simple buffer flows of the 
same flow type are generally lower than observed for the low shear laminar flow, with 40% 
and 80% reduction observed, respectively (Figure 3.5C–D). 
3.2.4 Evaluation of potential plasma protein effects on other VTC material types  
To evaluate whether the observed negative plasma protein effect on particle flow 
adhesion is unique to PLGA or extends to particles of other material types, adhesion of 
sLea-coated polystyrene (PS) spheres to activated HUVECs from laminar blood flow was 
evaluated similar to the PLGA assays. The size and surface charge of the sLea-coated PS 
particles were comparable to that of PLGA spheres evaluated (Table 3.2). In contrast to 
PLGA particles, the adhesion of 5 µm PS  particles (similar sLea density as PLGA particles) 
in whole blood is higher than their adhesion in buffer flow similar to our previous reports 
(Figure 3.6A)2,15.  
Table 3.2 Zeta potential measurement for 2 µm particles 
Material  Surface Medium 
Zeta Potential 
(mV) 
PS sLea 50% Plasma (in PBS) -6.5 +/- 2.5 
PLGA sLea 50% Plasma (in PBS) -4.6 +/- 3.2 
 
Moreover, the binding levels of PS in whole blood are comparable among all donor bloods 
evaluated. As such, there is no significant difference in PS adhesion between most low- 
and high- binding donor blood assays in contrast to that observed with PLGA (e.g., 
compare donor D to donors C and H in Figure 3.6A). A quick analysis of the blood flow 
adhesion of sLea-coated silica particles in blood flow relative to RBCs-in-VB and, similar 
to PS  yielded a mild reduction in blood flow relative to PLGA (Figure 3.7). This 
observation that particles of other materials main robust blood flow adhesion suggests that 
the plasma  
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  Figure 3.6 Adhesion of sLea–coated PS spheres or anti-ICAM-coated PLGA spheres to 
activated HUVEC under various flow conditions. (A) Adhesion of 5 μm sLea–
coated PS spheres in laminar whole blood and buffer flows to activated HUVEC at 
200 s-1 for 7 human subjects. N = 2 (distinct trials) for each blood bar. (B) Average 
adhesion of 4.6 μm anti-ICAM-coated PLGA spheres to activated HUVEC from 
laminar buffer, plasma, or whole blood flow of three low PLGA binding donors at 
200 s-1. Laminar flow was run for 5 min. Particle concentration in flow = 5 × 105 
spheres/mL. sLea density = 1,800 +/- 200 sites/μm2 (SEM) and anti-ICAM-1 
density = 3500 +/- 500 sites/μm2 (SEM). N = 3 distinct trials (donors) for the plasma 
and blood flow assays. ns = Not significant at 99% confidence interval.  
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Figure 3.7 Adhesion of 500 nm sLea-coated PLGA, polystyrene, and silica spheres to 
activated HUVEC in blood flow relative to RBCs-in-VB. Site densities (#/µm2) 
were obtained as follows: PLGA 3200 +/- 900; PS 3100 +/- 20; Si 4400 +/- 200. 
Particle concentration in flow = 1 × 106 spheres/mL. *= significant at 99% 
confidence relative to PLGA trial, **= significant at 99% relative to PS trial.   
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protein corona effect observed for PLGA spheres is likely due to polymer material 
characteristic, rather than targeting ligand chemistry/interaction, inducing differential 
plasma protein adsorption. Indeed, when experiments were performed with anti-ICAM-1 
(antibody)-coated PLGA spheres, a similar negative binding trend was observed for these 
particles as was seen with the sLea-coated PLGA spheres (Figure 3.6B); yet, in our previous 
work we show substantial binding of anti-ICAM-1 coated PS microspheres in human blood 
flow assays16. Overall, the successful binding of sLea-coated PS spheres in blood flow 
shown in Figure 3.6A (and anti-ICAM-1 coated PS spheres in the aforementioned previous 
publication) highlights that the lack of PLGA binding to HUVECs in blood flow is not due 
to human blood components negatively affecting the functionality of the HUVEC-
expressed protein target. Finally, we evaluated whether incorporation of polyethylene 
glycol (PEG) chains alters the HUVEC binding of PLGA particles. PEG chains were 
conjugated to the surface of 1.4 µm PLGA spheres at a density of 16,000 site/µm2 estimated 
to be in the brush conformation as we previously described16. In addition, a similar sLea 
density as the non-PEGylated particles was attached to the chain ends. The PEGylated 
PLGA spheres demonstrate the same negative adhesion trend in whole blood flow as 
observed for non-PEGylated PLGA spheres (Figure 3.8). The adhesion trend for a high-
HUVEC binding donor (L) versus a low-HUVEC binding donor (J) is also the same as 
observed for non-PEGylated PLGA spheres. In our previous publication, we show 
PEGylated 1.4 µm PS spheres to effectively bind to activated HUVECs from human blood 
flow16. 
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Figure 3.8 Adhesion of PEGylated and non-PEGylated 1.4 μm sLea-targeted spheres to 
HUVEC in laminar buffer or whole blood flow at 200 s-1 (5 min).  A PEG density 
of 16,000 site/μm2 estimated to be the brush conformation is used.  sLea density = 
1,800 +/- 200 sites/μm2 for both PEGylated and un-PEGylated particles.  Particle 
concentration in flow = 5 × 105 particles/mL. ns = Not significant at 99% 
confidence interval.   
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3.2.5 Characterization of protein adsorption on PLGA versus PS spheres 
To further probe whether differential protein adsorption on PLGA particles relative 
to PS is the cause of their differential adhesion to activated HUVECs in blood flow, the 
plasma protein corona was evaluated on sLea-coated particles via SDS-PAGE for PS and 
PLGA particles in low-HUVEC and high-HUVEC binding donors. Figure 3.8A shows a 
representative SDS gel for the 5 µm PLGA and PS spheres. There were visible differences 
in the corona acquired by PS microspheres opsonized for 1 hour in plasma (incubation 
followed by washing in buffer) and the corona found on PLGA spheres (Figure 3.9A: Lanes 
2 and 5 versus 3 and 4). Interestingly, there were also visible differences in the corona 
acquired by PLGA opsonized in plasma of a low HUVEC versus a high HUVEC PLGA 
binding donor (Lane 3 versus 4) particularly at the 150 kDa mark where PLGA spheres 
appear to acquire more proteins in the plasma that supported low PLGA flow adhesion 
compared to plasma that supported high PLGA binding. The corona acquired by PS 
microspheres was similar with opsonization in a low or high-HUVEC binding donor (Lane 
2 versus 5). Evaluation of the corona of PLGA particles incubated in low-HUVEC binding 
plasma at various time points, from 0 to 60 min, suggests there is a correlation between the 
presence and intensity of the 150 kDa band on the SDS gel for PLGA and the extent of 
reduction in particle blood flow adhesion to HUVECs as shown in Figure 3.9B. The plasma 
protein interference with binding was also shown to occur as early as 30 secs of particle 
exposure to plasma/blood and maximizes after only 5 min of exposure. Further analysis 
via mass spectrometry shows that the corona on sLea-PLGA particles (found in both high 
and low HUVEC binding donors) contains unique peptides not found in the corona of sLea-
PS spheres opsonized in the low HUVEC binding donor plasma as depicted in Figure 3.9C 
57 
 
(Table 3.3). An additional subset of proteins found in the low-HUVEC binding PLGA 
corona but absent from the high-HUVEC binding sLea-PLGA corona is listed Table 3.4. 
Taken together, these tables list all the proteins found uniquely in the low-HUVEC binding 
PLGA-sLea corona but not in the PS-sLea corona of the same low-HUVEC binding donor. 
A majority of the unique peptides found on PLGA (particularly when opsonized in low 
PLGA binding blood) are related to different subclass/subtype of immunoglobulins that 
belong to a cluster associated with proteins similar in structure to chain L of the insulin 
growth factor (IgF-Ii) antibody complex. 
To preliminarily confirm that large immunoglobulins such as ones identified above 
are involved in the diminished adhesion of PLGA particles in human blood, we evaluated 
the buffer flow adhesion of sLea-coated PLGA spheres opsonized for 1 hour in 25% plasma 
of a low PLGA binding donor depleted of 98% of the albumin and all immunoglobulins 
using a commercial depletion kit (PureProteome Depletion Kit; EMD Millipore) and 
compared to the adhesion of the same particles soaked in non-depleted plasma of the same 
donor. PLGA particles opsonized with depleted 25% plasma displayed the same high level 
of binding in buffer flow as non-opsonized particles whereas particle opsonized in non-
depleted, 25% plasma continued to exhibit low adhesion as was the case for non-depleted, 
100% plasma (Figure 3.10). Furthermore, when the PLGA particles were opsonized with 
5% plasma (non-depleted) to account for the reduction in the total protein in the protein-
depleted 25% plasma, particle adhesion was still significantly reduced compared to non-
opsonized particles. 
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3.3 Discussion 
The data presented here show that PLGA VTCs do not effectively adhere to 
inflamed HUVECs in laminar and pulsatile flow patterns with shear rates ranging from 
200-1000 s-1. We conclude that this phenomena is linked to the unique adsorption of 
specific “negative proteins” onto the surface of PLGA particles. This conclusion is 
supported by data from control experiments that show higher binding of PLGA particles 
with buffer and RBC-in-Buffer flows compared to the values observed in whole blood or 
plasma-only flows of the same flow type and shear magnitude. Also, a preliminary mass 
spectrometry analysis of the hard protein corona on particles revealed unique proteins, 
mostly immunoglobulin subclasses/subtypes, found in the protein corona on PLGA but not 
in the corona on PS particles when exposed to the same donor blood. It is likely that PS 
particles do not exhibit reduced adhesion in human blood (or plasma) flow due to the 
critical negative plasma proteins having a low affinity for these materials. This assertion 
that different material chemistry affects the type of adsorbed plasma proteins on particles 
of similar size and surface charge is in line with a previous report by others. Specifically, 
Deng et al. reported that nanospheres of different metal oxides having the same size and 
surface charge adsorb different plasma proteins10. We also find that the negative effect of 
plasma proteins on the adhesion of PLGA particles in blood flow was apparent for all 
particle sizes explored, from 4.6 µm down to 330 nm, despite the fact that particle size is 
known to affect the quantity and quality of proteins in the corona of nanoparticles6,17. This 
lack of a major effect of PLGA particle size on their blood flow adhesion to HUVECs in 
this work may be due to the affinity of the relevant plasma proteins for PLGA surfaces not 
being significantly affected within the range of particle size  
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Figure 3.9 Analysis of proteins adsorbed to particle surfaces as a function of material type 
and plasma incubation time. (A) SDS-gel electrophoresis analysis of proteins 
adsorbed on PS (5 μm) and PLGA (5 μm) spheres after 1 hr incubation in plasma. 
(Lane 1) Molecular weight standard. Proteins adsorbed onto particle surfaces were 
analyzed from the following conditions: PLGA soaked in a high (Lane 2) and low 
(Lane 3) HUVEC binding donor plasma; PS soaked in a low (Lane 4) and high 
(Lane 5) HUVEC binding donor; and PLGA (Lane 6) and PS (Lane 7) soaked in 
1% BSA solution. The protein profile in a 0.4% plasma of the low (Lane 8) and 
high (Lane 9) HUVEC binding donor was run as well. (B) Correlation of the buffer 
flow (200 s-1 laminar) adhesion of plasma opsonized PLGA (4.6 μm) spheres as a 
function of plasma incubation time (bottom) with the presence/development of a 
protein band at ~150 kDa in the protein corona of PLGA spheres as a function of 
time as observed with SDS-gel electrophoresis analysis (top).  (C) A depiction of 
differential plasma protein (PP) adsorption on PLGA and PS spheres.  
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Table 3.3 Unique peptides found on PLGA particles in low-HUVEC binding plasma  
                                                                                         Molecular weight (kDa) 
Cluster of Chain L, Crystal Structure Of Igf-Ii Antibody Complex 
1 protein Len,Bence-Jones 24 
2 recombinant IgG4 heavy chain [Homo sapiens] 43 
3 
Chain A, Human Factor Viii C2 Domain Complexed To Human 
Monoclonal Bo2c11 Fab 23 
4 immunoglobulin lambda 2 light chain [Homo sapiens] 23 
5 
Chain H, Crystal Structure Of Human Anti-Steroid Fab 5f2 In Complex 
With Testosterone 24 
6 immunoglobulin variable region [Homo sapiens] 17 
7 unnamed protein product [Homo sapiens] 55 
8 
Chain A, Crystal Structure Of An Autoimmune Complex Between A 
Human Igm Rheumatoid Factor And Igg1 Fc Reveals A Novel Fc Epitope 
And Evidence For Affinity Maturation 26 
9 
Chain L, Crystal Structure Of Human 2909 Fab, A Quaternary Structure-
Specific Antibody Against Hiv-1 23 
10 
Chain L, Crystal Structure Of Fab Del2d1, A Deletion Variant Of Anti-
Influenza Antibody 2d1 23 
Cluster of actin, cytoplasmic 2 [Homo sapiens] 
11 POTE ankyrin domain family member F [Homo sapiens] 121 
12 PREDICTED: actin, aortic smooth muscle isoform 2 [Equus caballus] 37 
Cluster of v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 
[Homo sapiens] 
13 
Chain A, Crystal Structure Of Src Kinase Domain In Complex With 
Cgp77675 32 
Complement factor H-related protein 5 precursor 
14 complement factor H-related protein 5 precursor [Homo sapiens] 64 
Cluster of unnamed protein product 
15 unnamed protein product [Homo sapiens] 141 
Cluster of growth-inhibiting protein 25 [Homo sapiens] 
16 
Chain A, Crystal Structure Of Cleaved Human Alpha1-Antichymotrypsin 
At 2.7 Angstroms Resolution And Its Comparison With Other Serpins 41 
17 
Chain A, Alpha1-Antichymotrypsin Serpin In The Delta Conformation 
(Partial Loop Insertion) 45 
Apolipoprotein A-V precursor [Homo sapiens] 
18 apolipoprotein A-V precursor [Homo sapiens] 41 
Cluster of unnamed protein product [Homo sapiens] 
19 unnamed protein product [Homo sapiens] 139 
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Table 3.4 Unique peptides found on PLGA particles in low-HUVEC binding donor plasma 
and absent from PLGA particles exposed to high-HUVEC binding donor plasma 
                                                                                         Molecular weight (kDa) 
Cluster of Chain L, Crystal Structure Of Igf-Ii Antibody Complex 
1 immunoglobulin light chain [Homo sapiens] 23 
2 Ig lambda chain – human 25 
3 immunoglobulin lambda 2 light chain [Homo sapiens] 23 
4 immunoglobulin lambda light chain VLJ region [Homo sapiens] 28 
5 Ig A L 23 
6 Ig lambda chain NIG76 precursor – human 23 
7 immunoglobulin light chain variable region [Homo sapiens] 23 
8 Ig nonfunctional kappa-chain (C-region), partial [Homo sapiens] 12 
9 immunoglobulin light chain [Homo sapiens] 24 
10 immunoglobulin lambda light chain, partial [Homo sapiens] 23 
11 immunoglobulin lambda 2 light chain [Homo sapiens] 23 
12 Chain L, Tr1.9 Fab Fragment Of A Human Igg1 Kappa Autoantibody 23 
13 IgM kappa chain [Homo sapiens] 24 
14 
Chain L, Crystal Structure Of Anti-Hiv-1 Fab 537-10d In Complex With 
V3 Peptide Mn 23 
15 unnamed protein product [Homo sapiens] 57 
16 immunoglobulin lambda light chain VLJ region [Homo sapiens] 28 
17 
Chain L, Crystal Structure Of The Neutralizing Fab Fragment Abd1556 
Bound To The Bmp Type I Receptor Ia 22 
18 immunoglobulin kappa light chain variable region [Homo sapiens] 16 
Cluster of histidine-rich glycoprotein precursor [Homo sapiens] 
19 unnamed protein product [Homo sapiens] 60 
Cluster of beta-1-syntrophin [Homo sapiens] 
20 
syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic 
component 1) [Homo sapiens] 58 
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Figure 3.10 Adhesion of 5 μm PLGA particles at a low sLea density (200 +/- 200 sites/μm2) 
to HUVEC in laminar buffer flow at 200 s-1 (5 min). Particles were soaked for 1 
hour in 1 mL in PBS (0% plasma) or in low HUVEC binding donor plasma at 5% 
25%, or 25% with depletion of albumin and immunoglobulins prior to flow in 
buffer for 5 min. * = Not significant at 99% confidence interval relative to PBS 
control. 
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explored. Indeed, about a third or more of plasma proteins in the corona of ultra-small 
nanoparticles are reported to be conserved with changes in particle size6,17. Our results 
show that the extent of the negative adhesion effect of plasma proteins on PLGA particles 
is donor dependent, particularly for the largest spherical size evaluated. This “donor effect” 
is likely linked to variation in plasma protein composition, type, and amount of individual 
proteins, across different individuals, which results in different levels of the critical 
negative plasma proteins being absorbed on PLGA particles when exposed to different 
donor blood. Indeed, recent studies have reported the existence of significant plasma 
protein diversity within the general human population, irrespective of gender and ethnic 
background18,19. As such, we postulate that PLGA particles in the blood of low-HUVEC 
binding donors acquire a higher amount of the critical negative plasma proteins, due to 
higher abundance of these proteins, which leads to a greater reduction in their HUVEC 
adhesion in the flow of plasma from these donors than observed in the plasma of high-
HUVEC binding donors. This assertion is supported by the observation of a thicker protein 
band at the 150 kDa protein size range on the SDS-PAGE gel for the corona stripped from 
~5 µm PLGA particles soaked in plasma from a low-HUVEC binding donor compared to 
the corona obtained from ones soaked in plasma from a high-HUVEC binding donor. The 
significantly lower adhesion of the 330 nm spheres in the plasma flow of high binding 
donors relative to adhesion in viscous buffer versus the lack of a plasma protein impact on 
the adhesion of 5 µm spheres in the plasma flow of the same high binding donors relative 
to viscous buffer would suggest that effect of plasma proteins on particle adhesion is more 
pronounced for the smaller spheres. As aforementioned, protein adsorption processes are 
the result of thermodynamic gradients that depend on the space available, e.g., particle size, 
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for adsorption to take place17,20. As such, it is likely that the distinction between a high and 
a low HUVEC binding donor in terms of plasma protein concentration is less impactful 
when there is a small surface area for adsorption. However, it is also possible that the larger 
surface area for contact, and hence more copies of targeting ligand, presented to the EC 
monolayer by the 4.6 µm spheres facilitate a binding advantage relative to the smaller 
spheres for assays conducted at a fixed ligand density (e.g., 1.4 µm spheres), though the 
larger spheres also experience greater hydrodynamic forces (scale directly with particle 
diameter21) that disrupts their adhesion. Overall, in light of this robust negative effect of 
the plasma protein corona on the adhesion of the 330 nm PLGA spheres with an actual size 
range from ∼170–500 nm, it is anticipated that PLGA nanospheres with sizes in the 50–
100 nm range are likely to also exhibit negative adhesion in human blood flow. Future 
studies include modifying the particle fabrication techniques used here to obtain PLGA 
nanoparticles in this size range to confirm this assertion. Finally, though there was no 
significant donor effect observed with the adhesion of PS spheres in blood relative to buffer 
flow, the slight reduction in the adhesion of PS particles in the blood of donor A, which 
consistently conferred the greatest reduction in PLGA adhesion (Figure 3.4A), compared 
to adhesion of PS in the blood of other donors may suggest that particles of any material 
type can have their vascular-targeted adhesion negatively impacted at a high enough 
plasma concentration of the negative proteins in blood. 
The lack of a significant difference in the PLGA adhesion levels between plasma 
and whole blood flow assays for low HUVEC binding donors suggests that the effect of 
the adsorbed plasma proteins is large enough in these cases, i.e., high adsorption of critical 
negative proteins, to make any blood cell-particle interactions that may impact adhesion 
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level inconsequential (Figure 3.4A, donors A, C, H, J and N). Conversely, the level of 
adsorption of plasma proteins on PLGA in the blood of high HUVEC binding donors is 
likely not as robust such that PLGA adhesion is only mildly affected in the flow of plasma 
from these donors. However, when particle-blood cell interactions (e.g., collisions) that 
have previously been reported between microspheres and RBCs and WBCs15 are present 
in whole blood flow, it served to further disrupt particle adhesion. This explains the larger 
reduction in the adhesion of 5 µm spheres in whole blood assays relative to plasma for 
high-HUVEC binding donors. The distinction between plasma flow adhesion and whole 
blood adhesion is less pronounced for the smaller spheres evaluated likely due to a reduced 
(or possibly absent) effect of blood cell-particle interaction for the smaller sizes. We 
previously reported that the adhesion of 5 µm spheres are significantly reduced in laminar 
blood flow as the blood hematocrit, or RBC concentration, is increased from 30 to 45% 
while the adhesion of nanospheres and small microspheres remains the same or is slightly 
higher with the same increase in blood hematocrit15. Here, the presence of RBCs in flow 
helps concentrate the smaller particles at the wall relative to plasma flow2 but with no 
negative impact from blood cell interactions; hence the higher adhesion of the 330 nm 
particles in whole blood relative to plasma flows for high-HUVEC binding donors. 
However, the impact of a higher concentration of the 4.6 µm spheres at the wall in blood 
flow on their adhesion would be negated by the cell-particle collisions that tend to disrupt 
adhesion for this particle size. This cell-particle phenomenon also in part explains why the 
330 nm and 1.4 µm spheres exhibit significantly enhanced binding in RBC-in-buffer 
relative to buffer flow (Figure 3.1 C-D). 
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The fact that targeting ligand density affects the adhesion of PLGA particles in 
different donor blood would suggest that the critical negative proteins adsorbed on PLGA 
are interfering with particle-HUVEC binding by weakening the affinity of the receptor-
ligand interactions as alluded to in the discussion of the observed donor effect in the 
previous section. Specifically, in certain donor bloods (i.e., low HUVEC binding donors) 
where PLGA particles can attract a high amount of the critical negative proteins, the 
kinetics of the attached ligand is significantly weakened and hence a large reduction in the 
capacity of the targeted particle to bind in flow is observed irrespective of a high or low 
ligand density or, as aforementioned, whether or not the vascular wall interaction is 
occurring in whole blood (the presence of collisions from blood cells) or plasma flow 
(Figure 3.4). In other donor bloods where the concentrations of the negative plasma 
proteins are likely appropriately lower, PLGA adhesion is minimally affected in plasma 
flow when the PLGA particles are at a high targeting ligand density. However, there is still 
some moderate weakening of ligand kinetics occurring in these cases, which is highlighted 
by the significantly reduced particle adhesion when a low targeting ligand density (donors 
B, E and I) is present on the particle surface. For these donor bloods, the exaggeration of 
the negative adhesion of PLGA particles at low ligand density relative to high ligand 
density may not necessarily be due solely to greater changes in ligand affinity associated 
with a larger amount of adsorbed proteins on particles but could also be due to low avidity 
of the moderately weakened ligands. That is, there is not enough of the moderately 
weakened ligand to support adhesion at a fixed wall shear stress in flow. 
Finally, it is not surprising that PEGylation of PLGA particles has no apparent 
effect on their negative adhesion in human blood. While the use of PEG spacers located 
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between the material surface and the targeting ligand is a strategy that is often employed 
to reduce protein adsorption on VTCs, it is known that protein adsorption is always present 
at some basal level on PEG grafted VTCs. For example, Gref et al. showed that PEG-
coated surfaces can still support protein adsorption via direct interactions with the core 
material even at high PEG density, poly(lactic acid) (PLA), PLGA and poly(Ɛ-
caprolactone) (PCL) nanoparticles coated with the same high density of PEG where shown 
to adsorb different levels and types of protein on their surfaces22. However, it remains 
possible that use of an ultra-high surface PEG density resulting in minimal protein 
adsorption on the carrier surface may abate the negative effect of plasma23. In our ongoing 
work, we are exploring whether variation in PEG density and chain length can alter PLGA 
particle adhesion to the vascular wall in blood. 
3.4 Conclusions 
In this work, the adsorption of certain plasma proteins from human blood onto 
PLGA carriers were found to prevent these particles from effectively adhering to activated 
HUVECs in in vitro assays, an effect that was not observed for particles of other material 
types. Our results also show that the extent of the negative adhesion effect of plasma 
proteins on PLGA particles is dependent on specific blood donors and the targeting ligand 
density but not the targeting ligand type. Overall, the presented data suggests that specific 
knowledge of the plasma protein composition across different humans may be critical to 
VTC design and their successful clinical use, i.e., highlighting the need for a shift toward 
personalized medicine in the design of targeted therapeutics. Alternatively, it is possible 
that with a detailed understanding of the specific proteins that affect particle vascular 
targeting, novel biomaterials can be designed to resist the adsorption of these proteins in 
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order to achieve enhanced vascular targeting irrespective of the plasma composition of 
different individuals. A potential limitation to this study, however, is in our evaluation of 
blood flow adhesion in vitro over culture endothelial cells. A detailed conclusion of the 
effect of plasma proteins on particle margination may necessitate evaluation via in vivo in 
animal models—though differences in plasma protein composition between human and 
common animals used in experimental research may complicate such analysis. Our future 
studies will aim to specifically identify which individual plasma proteins in human blood 
are associated with low PLGA margination as well as to further investigate the existence 
of this plasma protein effect for other biomaterials. Furthermore, we will conduct 
preliminary in vitro assays of particle margination in mouse blood flow to identify any 
potential difference in PLGA (and other biomaterials) adhesion relative to human blood as 
a first step toward future in vivo analysis of plasma protein modulation of vascular-targeted 
particle margination. 
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CHAPTER 4: PLASMA IMMUNOGLOBULINS DRIVE CORONA-INDUCED 
NEGATIVE ADHESION EFFECTS ON PLGA DRUG CARRIERS 
 
ABSTRACT 
 The plasma protein corona has been identified to have deleterious effects on 
nanoparticle targeting efficiency to reactive substrates as well as human blood flow in vitro. 
Although protein size has been implicated in corona-induced negative targeting effects, the 
role of specific proteins in this process remains largely unknown. This work explores the 
adhesion of PLGA drug carriers pre-soaked in plasma which has been depleted and 
replaced with specific immunoglobulin proteins, in effort to pinpoint which 
immunoglobulin class is largely responsible in causing corona-induced negative adhesion. 
Here, it is observed that particles soaked in immunoglobulin depleted plasma enjoy full 
adhesion recovery relative to non-depleted plasma. Furthermore, particles soaked in 
immunoglobulin depleted plasma spiked with an antibody solution containing ~70% IgA1 
causes full adhesion knockdown resulting in adhesion levels similar to that observed with 
particles pre-soaked in non-depleted plasma (~60% reduction relative to buffer). However, 
when particles were soaked in immunoglobulin depleted plasma spiked with antibody 
solutions with > 95% IgG and IgM, minimal adhesion knockdown was observed (4-25% 
reduction relative to buffer). Overall, this study reveals that corona-induced negative 
adhesion of PLGA drug carriers is largely driven by the adsorption of IgA1 protein in blood 
plasma. Furthermore, this work could serve as an important parameter in predicting 
targeted drug carrier adhesion efficiency in human blood flow.   
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4.1 Introduction 
 The rapidly forming NP plasma protein corona has been implicated in a number of 
drug delivery phenomena, including clearance, biodistribution, circulation time, and 
recently—NP targeting1–5. It has been observed that the corona exerts a negative impact on 
deposition of nanoparticles to reactive surfaces and targeted cell uptake efficiency in the 
presence of fetal bovine and human serum. These studies have typically viewed the corona 
as a “shell” which screens the ligands from interacting with their receptors4,5. This corona 
effect has been described to jeopardize ligand function, conformation, and surface receptor 
recognition.   
Although protein size (i.e., molecular weight) has recently been implicated as an 
important contributor to the observed negative corona effects on targeted NP deposition4, 
the role of individual proteins in driving corona-induced effects remains largely unknown. 
Previously, immunoglobulins (Igs) were linked to plasma-induced negative adhesion of 
PLGA microparticles in blood flow. Here, the impact of Igs is further explored via probing 
the role of specific Ig protein types in modulating the extent of corona-induced negative 
adhesion of PLGA drug carriers. Specifically, PLGA nanoparticles pre-soaked in depleted 
plasma (IgG removed versus all Igs removed), and buffer and non-depleted plasma are 
tested in a parallel plate flow chamber assay. Furthermore, IgG, IgA, and IgM are re-added 
to Igs depleted plasma to test whether the presence of a specific protein re-establishes 
adhesion reduction as observed with particles soaked in non-depleted plasma. It is observed 
that re-addition of an immunoglobulin solution containing >20% IgA1 mass fraction in the 
soaking medium results in nearly full adhesion knockdown. Overall, this work suggests 
that corona-induced effects on PLGA adhesion in blood flow are heavily linked to plasma 
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IgA1 and to a lesser extent, IgG and IgM. Furthermore, this work could be used to predict 
PLGA drug carrier adhesion efficiency in blood flow based on an individual’s Ig 
composition and concentration.  
4.2 Results 
4.2.1 Assessment of immunoglobulin depletion kit specificity and efficiency  
Commercially obtained depletion kits were employed for the removal of IgG, IgA, 
and other immunoglobulins from human plasma. The efficiency and specificity of the Ig 
depletion columns employed here were assessed via ELISA and SDS-PAGE of the 
depleted plasma samples as well as the isolated protein solutions obtained from column 
elution. For the IgG depleted sample, a Protein A column was employed. Protein A is 
known to bind IgG with high affinity and IgM, IgA with weak affinity. IgA depletion was 
performed via an IgA depletion column which consisted of affinity purified anti-IgA beads 
designed to only bind human IgA. To obtain all Igs depleted plasma, an 
Immunoglobulin/Albumin depletion kit was employed which has been tested via ELISA 
by the manufacturer and shown to deplete >99% of all Igs in plasma or serum. In addition, 
IgG + IgA depleted plasma was obtained by sequential exposure of plasma to the Protein 
A column followed by the IgA depletion column. Table 4.1 lists the % protein retained in 
plasma post exposure to the different columns/beads relative to non-depleted plasma 
obtained via sandwich ELISA. IgG, IgM, and IgA1 together constitute ~98% of all 
immunoglobulin content and thus is taken as an approximation for the total plasma Ig 
content. Overall, the Protein A column designed to deplete IgG showed high specificity, 
removing ~92% of plasma IgG and retaining 80% of IgA1. Some loss in IgM was observed 
(~50%). On the other hand, the IgA depletion column was rather nonspecific as the IgA 
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depleted sample was also devoid of ~99% of IgG and IgM. Similar results were observed 
for the IgG + IgA depleted sample. The Igs depleted plasma showed no detectable signal 
for IgG, IgM, or IgA1 which is consistent with manufacturer testing.    
 
 
 
 
 To test whether specific Igs can re-establish corona-induced adhesion reduction, 
the isolated products obtained from the IgG and IgA depletion columns were collected via 
elution with glycine. Figure 4.1A shows the fractional Ig composition (measured via 
ELISA) collected from the Protein A column (IgG*), IgA depletion column (IgA*), and 
IgA* x-IgG, which was obtained by collecting the eluted product from the IgA column 
with IgG depleted plasma. In addition, an SDS-PAGE of the depleted plasma and eluted 
samples for IgG* and IgA* is shown in Figure 4.1B-C. Since IgG, IgM, and IgA1 constitute 
~98% of all Ig content, the normalized Ig fraction is based on the sum of the abundance of 
these three proteins. Contributions from IgA2, IgD, and IgE were not tested or included in 
these assays as it is known these proteins have a much lower concentration in blood than 
IgG, IgM, and IgA1. IgG* was approximately 95% IgG, 3% IgM, and 2% IgA1. IgA* 
contained mostly IgG (~76%) but did contain ~14% more IgA1 by volume along with a 
slight increase in IgM content relative to IgG*. For IgA* x-IgG, the IgA1 fraction was 
~72%, IgG ~17%, and IgM, ~11%.  In addition, commercial IgM was employed which is 
tested by the manufacturer via HPLC to have purity of > 95%.  
 
 
Table 4.1 Assessment of Ig concentration post depletion column/bead exposure 
Plasma sample type % IgG retained % IgM retained % IgA1 retained 
IgG depleted 7.9+6.4 54.4+1.6 80.2+1.5 
IgA depleted 1.4+0.7 1.0+0.7 0 
IgG + IgA depleted 1.4+0.3 0 0 
Igs depleted 0 0 0 
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Figure 4.1. A) ELISA Quantification of plasma IgG, IgM, and IgA1 fractions in the eluted 
product from the Protein A column (IgG*), IgA depletion column (IgA*), and in 
the case where IgG depleted plasma was exposed to the IgA depletion column 
(IgA* x-IgG). B) SDS-PAGE of IgG depleted plasma and IgG*: Lane 1 – standard, 
Lane 2 – 2% plasma, Lane 3 – 2% plasma (IgG depleted), and Lane 4 – IgG*. C) 
SDS-PAGE of IgA depleted plasma and IgA*: Lane 1 – standard, Lane 2 – 2% 
plasma, Lane 3 – 2% plasma (IgA depleted), and Lane 4 – IgA*. 
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4.2.2 Evaluation of PLGA particle adhesion pre-soaked in depleted plasma  
 The goal of this work is to evaluate the role of individual Ig proteins in modulating 
the previously observed corona-induced negative adhesion of PLGA particles in blood 
flow6. 500 nm PLGA nanoparticles are used in this work given their relevance to drug 
delivery. IgG is a natural candidate to consider since this protein alone constitutes ~75% 
of the total Ig content in plasma. In these experiments, Sialyl-lewisa (sLea) coated PLGA 
particles (2300 + 500 sites/µm2) were pre-soaked for 1 hour in IgG depleted plasma, IgG 
+ IgA depleted plasma,  all Igs depleted plasma, non-depleted plasma, or buffer followed 
by the PPFC assay in plasma free blood flow (i.e., RBCs-in-VB, at 38% hematocrit) over 
inflamed human umbilical vein endothelial cells (HUVECs). All data was normalized to 
the adhesion obtained when pre-soaking in PBS buffer. 25% plasma solutions were 
employed for these assays since depletion kit utility requires a plasma dilution step. In 
addition, due to the nonspecific nature of the IgA depletion column, plasma depleted of 
IgA only was not possible.  
Although PLGA particles soaked in only IgG removed plasma did not significantly 
recover adhesion, pre-soaking in plasma depleted of IgG + IgA or all Igs resulted in 
significant adhesion recovery when averaged across multiple donors (Figure 4.2A). PLGA 
particle adhesion pre-soaked in IgG-depleted plasma was also explored for individual 
donors and interestingly, significant adhesion recovery was observed only in the case of 
particles soaked in IgG-depleted plasma from donor N (Figure 4.2B) which also showed a 
high plasma IgG concentration (Figure 4.2C). All donors exhibited significant adhesion in 
Igs depleted plasma.    
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Figure 4.2. A) Adhesion of slea-targeted PLGA particles soaked for 1 hr in 25% plasma 
(No depletion), 25% IgG depleted plasma, 25% IgG + IgA depleted plasma, 25% 
Igs depleted plasma, prior to a parallel plate flow chamber assay in RBCs-in-VB 
(38% hematocrit) at 200 s-1. * = p <0.01 compared to 25% (No depletion) trial, 
concentration 1 × 106 # particles/mL, n = 3 (averaged across donors N,F,D,V). B) 
PLGA particle adhesion in the same mediums as (A) but on a donor-to-donor basis. 
C) ELISA of IgG concentration in the various donors. 
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4.2.3 Evaluation of PLGA particle adhesion pre-soaked in Igs depleted plasma with 
re-addition of specific Ig proteins 
In addition, particles were also pre-soaked in Igs depleted plasma which had been 
spiked with IgG*, IgA*, IgA* x-IgG, and commercial IgM to probe whether replacement 
of approximately individual Ig protein classes in the soaking medium is solely capable of 
re-establishing corona-induced negative adhesion (Figure 4.3). IgG* was re-added to 25% 
Igs depleted plasma soaking medium at ~5 mg/mL, mainly to test whether a high 
physiological IgG concentration could explain the lack of sensitivity to IgG depletion. In 
addition, a concentration of ~5 mg/mL is similar to donor N, which showed unique 
sensitivity to IgG depletion (Figure 4.3A). Overall, minimal adhesion knockdown of PLGA 
particles was observed when pre-soaked in Igs depleted plasma + 5 mg/mL IgG* (Figure 
4.3A). However, soaking in Igs depleted plasma spiked with IgA* at ~1 mg/mL or IgA* 
x-IgG at a physiological IgA concentration resulted in significant adhesion knockdown 
resulting in no statistical difference relative to the non-depleted plasma control.  A 
physiological IgA concentration chosen for the IgA* x-IgG sample since this solution was 
mostly IgA. In addition, commercial IgM was re-added at 0.2 mg/mL which is consistent 
with the physiological level for donor D and resulted in significant adhesion knockdown, 
but to a lesser extent than the re-addition of IgA* or IgA* x-IgG. Physiological 
concentrations of IgA1 and IgM were based on the ELISA measurements in Figure 4.3B. 
Figure 4.3C shows the SDS-PAGE of the various solutions that the particles were pre-
soaked in prior to the adhesion assay.  
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Figure 4.3. A) Adhesion of slea-targeted PLGA particles soaked for 1 hr in 25% plasma 
(No depletion), 25% Igs depleted plasma and  25% Igs depleted plasma + 5 mg/mL 
IgG*, 1 mg/mL IgA*, IgA* x-IgG, and commercial IgM prior to a parallel plate 
flow chamber assay in RBCs-in-VB (38% hematocrit) at 200 s-1. * = p <0.01 
compared to 25% (No depletion) trial, concentration 1 × 106 # particles/mL. B) 
ELISA testing of IgA1 and IgM concentrations for different donors. C) SDS-PAGE 
of the 25% plasma solutions PLGA particles were soaked with prior to flow assay; 
Lane 1: molecular weight ladder, Lane 2: no depletion, Lane 3: IgG depleted, Lane 
4: IgA depleted, Lane 5: Igs depleted, Lane 6: Igs depleted + 5 mg/mL IgG*, Lane 
7: Igs depleted + 1 mg/mL IgA*, Lane 8: Igs depleted + 5 mg/mL IgG* + 1 mg/mL 
IgA*, Lane 9: IgA + IgG depleted. 
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4.3 Discussion 
 The data presented in this work seeks to pinpoint the role of specific plasma Ig 
proteins in orchestrating corona-induced negative adhesion of PLGA particles in human 
blood flow. The Ig population in human plasma is dominated by IgG, which comprises 
~75% of the human Ig content. Due to its high abundance, it was hypothesized that this 
protein is a major player in causing PLGA adhesion reduction. Surprisingly, depletion of 
IgG alone (Figure 4.2A) did not result in considerable recovery in adhesion for nearly all 
donors tested. An exception was observed in the case of particles soaked in IgG-depleted 
donor N plasma (Figure 4.2B). However, when particles were soaked in donor N plasma 
depleted of all Igs and spiked with donor N IgG*, minimal adhesion knockdown was 
observed, suggesting that adhesion knockdown depends on the presence of other Igs. When 
averaged across multiple donors, depletion of IgG + IgA as well as all Igs resulted in full 
adhesion recovery (i.e. no difference relative to soak in buffer) (Figure 4.2A). Although 
depletion of IgG alone from the soaking medium did not result in significant particle 
adhesion recovery, this could be linked to differences in the IgG concentration as some 
donors (i.e. F,D) had lower IgG concentrations than donor N where an effect was observed 
upon IgG removal. The potential for IgG to re-establish adhesion reduction was probed via 
soaking particles in 25% Igs depleted plasma + 5 mg/mL IgG* (a high physiological 
concentration); however, no significant effect was observed suggesting that IgG, despite 
being the most abundant IgG protein, is likely at most a minor contributor to the reduced 
PLGA adhesion observed post plasma soaking (Figure 4.3). However, when PLGA 
particles were soaked in Igs depleted plasma spiked with solutions of higher IgA fraction 
(i.e. IgA*, IgA* x-IgG), significant adhesion knockdown was observed, suggesting this 
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protein to be a major player in orchestrating PLGA adhesion reduction. Other Igs such as 
IgM likely exhibit secondary roles evidenced by adhesion knockdown observed with 
particles soaked in IgM spiked solutions (Figure 4.3).  
4.4 Conclusions 
 Overall, this work confirms the role of Igs in driving plasma-induced PLGA 
adhesion reduction through Ig depletion and re-addition experiments.  The most abundant 
Ig protein, IgG, surprisingly exhibits a minor, if any role in establishing plasma-induced 
PLGA adhesion reduction. Contrastingly, IgA appears to be the critical Ig class responsible 
for orchestrating PLGA adhesion reduction.  Further work will seek to limit IgA adsorption 
via covalent coating with dysopsonin proteins such human serum albumin and 
apolipoproteins.  
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CHAPTER 5: IMPACT OF BIODEGRADABLE MATERIAL TYPE ON 
CORONA-INDUCED NEGATIVE ADHESION OF DRUG CARRIERS IN 
HUMAN BLOOD FLOW 
 
ABSTRACT 
Previous work has revealed that the plasma protein corona in blood flow 
significantly reduces vascular-targeted drug carrier (VTC) adhesion efficiency in vitro, 
particularly for poly(lactic-co-glycolic) acid (PLGA) microspheres. However, the impact 
of the plasma protein corona on VTC adhesion efficiency of other common biodegradable 
materials (e.g., polylactic acid (PLA), polycaprolactone (PCL)) remains relatively 
unknown. Here, the potential role of biodegradable VTC material type on the extent of 
corona-induced adhesion reduction is explored via in vitro parallel plate flow chamber 
(PPFC) assays. Overall, it is observed that the extent of corona-induced VTC adhesion 
reduction is tempered depending on the material type employed. Specifically, PCL 
exhibited mild reduction in whole blood (WB) (~25% reduction) compared to PLA and 
PLGA (~75% reduction). In addition, PCL is observed to adsorb less immunoglobulin (Ig) 
protein than PLA or PLGA, a protein type previously linked as a major player in this 
process. In addition, increased ligand density was observed to mitigate corona-induced 
effects on PLA and PLGA. Overall, this work suggests that hydrophobic materials such as 
PCL may have better potential as a vascular-targeted carrier for intravenous therapy 
application due to its superior adhesion in whole blood relative to plasma-free blood 
compared to other commonly employed biodegradable drug carriers. 
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5.1 Introduction 
Previously, rapid plasma protein adsorption onto PLGA-VTCs was shown to 
drastically reduce VTC adhesion efficiency to human umbilical vein endothelial cells 
(HUVECs) in human blood flow. In addition, the extent of plasma-associated reduced 
adhesion was dependent on ligand density, human donor, and flow profile and these effects 
were linked to the adsorption of large immunoglobulins in the PLGA corona, which were 
not significantly present in the polystyrene (PS) corona1. Although PLGA VTCs exhibited 
significant corona-induced adhesion reduction in blood flow, the impact of the protein 
corona on the adhesion efficiency of other common biodegradable VTCs such as PLA and 
PCL remains relatively unknown. Biodegradable polyesters, including PLGA, PLA, and 
PCL differ in their hydrophobicity which is a critical parameter that influences the type, 
amount, and conformation of surface-bound corona proteins2,3. This work explores the role 
of biodegradable polyester VTC material type on the adhesion efficiency of sialyl-Lewisa  
(sLea) and anti-ICAM-1 targeted NPs (~500 nm in diameter) over a range of ligand 
densities in human blood flow via in vitro PPFC assays. Non-pegylated (non-PEG) 
particles are employed in the experiments throughout this study to highlight the differential 
impact of material type in any observed effect of the plasma protein corona, which can 
shed light on the extent of surface modification required for VTCs of different materials to 
successfully reduce or alter plasma protein adsorption. Furthermore, the field has shown 
growing interest in exploiting the protein corona by tailoring its composition to favor 
adsorption of specific proteins for cell targeting4–10.  
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5.2 Results 
5.2.1 Evaluation of the adhesion efficiency of various VTCs in human blood flow 
 The focus of this work is to evaluate the performance of common biodegradable 
polyesters in modulating the impact of the protein corona on targeted drug carrier adhesion 
in human blood flow. PS particles serve as a control in these assays to compare with 
previous publications. VTC adhesion was evaluated in a PPFC assay in whole blood. The 
percent (%) control adhesion of sLea-targeted VTC material types with similar size (Table 
5.1) and ligand density in WB relative to that in the plasma-free blood (RBCs-in-VB) is 
shown in Figure 5.1.  PLGA and PLA experienced major adhesion reduction in blood flow 
(>60% reduction), whereas PCL and PS spheres maintain substantial resistance to the 
plasma protein corona effect where only ~25% reduction in control adhesion is observed.  
Table 5.1. Particle size characterization  
Material Z-Average (nm) PDI 
PLA 635 0.25 
PLGA 428 0.18 
PS 529 0.12 
PCL 600 0.27 
 
5.2.2 Evaluation of targeting ligand density and type on blood flow adhesion of 
biodegradable VTCs 
The extent of PLGA plasma-associated adhesion reduction depends on the targeting ligand 
density as previously observed with sLea-targeted microspheres1. In Figure 5.2A, the sLea 
site density for the different biodegradable polyesters was increased to ~15,000 sites/µm2 
and is likely close to the saturation limit for these particles. Nearly full adhesion recovery 
in whole blood relative to RBCs-in-VB was observed for these materials evidenced by 
small differences between adhesion in whole blood and RBCs-in-VB.  
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Figure 5.1 HUVEC adhesion (% relative to RBCs-in-VB Control) for PLGA, PLA, PCL, 
and PS VTCs in whole blood after 5 min of flow at a shear rate of 200 s-1. The site 
densities with standard error were calculated for each material: PLGA 8600 +/- 
600; PLA 7500 +/- 50; PCL 7100 +/- 1200; PS 9200 +/- 300.  
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In addition, the ligand type (sLea versus anti-ICAM-1) was explored for the 
biodegradable materials at a lower site density in Figure 5.2B. No significant difference in 
adhesion reduction was observed across these ligand types for the biodegradable materials. 
In addition, PLGA particles were coated with a high anti-ICAM density to test whether 
significant recovery in adhesion is possible with other ligand types. Figure 5.2C shows that 
even at ~19,000 anti-ICAM-1 sites/µm2, no significant adhesion recovery is observed. This 
is an important observation as this site density range is near saturation and thus, for anti-
ICAM-1 particles site density is unable to circumvent plasma induced adhesion reduction.  
5.2.3 Characterization of zeta potential and protein corona profile on VTCs 
As observed in Figure 5.1, the negative impact of plasma proteins is dependent on 
the type of biodegradable VTC. To better understand these results, the zeta potential and 
protein profile were evaluated for these materials. Highly similar zeta potential values were 
observed across all material types. Evaluation of the protein profile via SDS-PAGE 
revealed differences in the amount of specific protein bands, namely at the 50 and 150 kDa 
mark. Specifically, it was observed that PLGA and PLA coronae formed in WB exhibit 
increased adsorption (1.47 +/- 0.10 folds via ImageJ) of 150 kDa protein (e.g., 
immunoglobulins) relative to PCL (Figure 5.2B). In addition, PCL exhibited increased 
albumin adsorption (1.55 +/- 0.10 increase in relative intensity) compared to PLGA and 
PLA particles. In Figure 5.3C, it is observed that PS particles also adsorb increased albumin 
relative to PLGA. 
 
 
 
88 
 
Figure 5.2 A) HUVEC adhesion (% relative to RBCs-in-VB Control) for PLGA, PLA, 
PCL, and PS VTCs in whole blood after 5 min of flow at a shear rate of 200s-1. Site 
densities for A) were obtained as follows: PLGA 15300 +/- 900; PLA 12300 +/- 
100; PCL 14500 +/- 700. B) Effect of targeting ligand type on adhesion efficiency, 
with the following site densities (#/µm2): sLea, (All materials) 3000 +/- 500; anti-
ICAM-1, PLGA 3700 +/- 200; PLA 4000 +/- 100; PCL 3200 +/- 20. C) HUVEC 
adhesion of high density anti-ICAM-1 coated PLGA particles (19300 +/- 500) 
versus 3700 +/- 200 sites/µm2. Particle concentration was fixed to 1 × 106 
particles/mL in all assays.  
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Figure 5.3 A) Zeta potential measurements for sLea-coated VTCs of PLGA, PLA and PCL. 
B) SDS-PAGE of surface bound protein coronae formed on PLGA, PCL, and PLA 
VTCs exposed to VB and ACD plasma. Lane 1: molecular weight standard, Lane 
2: PLGA corona from VB soak, Lane 3: PCL corona from VB soak, Lane 4: PLA 
corona from VB soak, Lane 5: PLGA corona from plasma soak, Lane 6: PCL 
corona from plasma soak, Lane 7: PLA corona from plasma soak. C)  SDS-PAGE 
of surface bound protein coronae formed on ~5 µm PLGA and PS VTCs exposed 
to VB and ACD plasma. Lane 1: molecular weight standard, Lane 2: PS corona in 
low HUVEC binding donor plasma, Lane 3: PLGA corona from high HUVEC 
binding donor plasma, Lane 4: PLGA corona in high HUVEC binding donor 
plasma, Lane 5: PS corona from high HUVEC binding donor plasma 
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5.2.4 Evaluation of covalent attachment of albumin to improve PLGA adhesion 
efficiency in human blood flow 
 Although higher site densities resulted in significant adhesion recovery of sLea-
coated spheres, anti-ICAM-1 coated particles did not benefit from an increased targeting 
ligand density. Thus, tailoring the PLGA plasma protein corona is explored in an attempt 
to mitigate the negative adhesion impact of the protein corona on PLGA particles. 
Specifically, covalent attachment of human serum albumin (HSA) to the PLGA surface is 
performed. Recent literature has exploited HSA attachment to nanoparticles to increase 
circulation time and limit non-specific adsorption of opsonin proteins (e.g., 
immunoglobulins)11,12. Figure 5.4 shows that covalent attachment of HSA to PLGA-anti-
ICAM-1 particles does not improve the adhesion efficiency in whole blood relative to 
RBCs-in-VB.  
5.3 Discussion 
The experimental data presented in this work shows that the choice of 
biodegradable VTC material type has a substantial impact on the adhesion efficiency in 
human blood flow and targeting ligand density was shown to play an important role in the 
extent of the adhesion differences between material types. Overall, PLGA and PLA 
particles exhibited major reduction in blood flow whereas PCL particles were largely 
resistant to corona-induced. However, the negative effect of the plasma protein corona on 
PLGA and PLA sLea particle adhesion for all materials was shown to be largely mitigated 
when high ligand density (near saturation) was used (Figure 5.2A). In addition, the role of 
ligand type was briefly explored and found to play a minimal role with the exception that 
high density anti-ICAM-1 coated PLGA 
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Figure 5.4 HUVEC adhesion (% relative to RBCs-in-VB Control) for PLGA anti-ICAM-
1 particles (6600 +/- 50 sites/µm2) along with PLGA anti-ICAM-1 particles 
covalently linked with human serum albumin (HSA) with 8000 +/- 140 anti-ICAM-
1 sites/µm2. ~3600 sites of human serum albumin were covalently coupled to the 
PLGA-HSA-anti-ICAM-1 particles confirmed via an anti-human Albumin-FITC 
antibody.  
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particles did not exhibit adhesion recovery in blood flow. This could be due to the slow 
kinetics of antibody interactions relative to selectin/sLea, thus preventing adhesion 
recovery with higher ligand surface coverage.  
Although ligand density was observed to abate the impact of the plasma protein 
corona at high ligand density, significant differences were observed at the lower site 
density ranges where PCL and PS experienced mild reduction in blood flow compared to 
PLGA and PLA. It is important to note that the optimal targeting density does not 
necessarily translate to the highest density possible.  Indeed, a recent study has shown that 
the optimal ligand density for superparamagnetic iron oxide (SPIO) NPs for different NP 
size and ligand type was at an intermediate density of ~10,000 ligands/µm2, potentially a 
result of receptor clustering effects13. Although this study employed a different particle 
ligand/receptor system, it suggests here that the high density data may not be optimal in 
vivo, due to increased non-specificity14. Now, in theory, it can be expected that upon 
plasma exposure for plasma-sensitive PLGA and PLA particles with a high targeting ligand 
density, the effective density would be lower and therefore the variability between particle 
material types would result in differences in targeting specifity. Thus, it is worthwhile to 
understand the differences in adhesion efficiency observed across material types at lower 
targeting ligand density.  
Given that the zeta potential of the materials studied here were largely similar in 
buffer and plasma, electrostatic interactions likely does not explain the large differences in 
adhesion induced by the plasma protein corona. Hydrophobicity, on the other hand, is 
known to vary significantly between these materials15. Furthermore, hydrophobicity is 
known to play a critical role in the magnitude, composition, and confirmation of the plasma 
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protein corona2. Specifically, increased hydrophobicity is associated with increased protein 
adsorption and acceleration of opsonization, leading to faster clearance from the 
bloodstream16. Since the amount of protein adsorption in the different coronae depends on 
hydrophobicity, this is a potential cause for differential adhesion due to plasma protein 
interaction. However, given the highly similar zeta potential readings across these 
materials, it is not expected that the amount of total protein adsorbed in the corona 
significantly varies between these materials. Thus, it is hypothesized that differences in the 
composition of the corona (i.e., abundance of particular proteins) caused by hydrophobicity 
is the driver of the observed differential adhesion interactions of the polyester particles. 
SDS-PAGE was performed in this work for PLGA, PLA, and PCL particles with the goal 
to understand the adhesion assay via correlation of the corona profile across different 
materials.  It is observed in Figure 5.2B and 5.3 that the VTC materials largely resistant to 
corona-induced adhesion reduction (PCL and PS) adsorbed less Igs and more albumin 
relative to poorly performing PLGA and PLA. The reduced Igs adsorption may explain the 
differential adhesion efficiency of PCL and PS particles relative to PLGA and PL since 
high molecular weight immunoglobulins (Igs) were previously implicated in orchestrating 
corona-induced adhesion reduction of PLGA microparticles in human blood flow1,17. 
Furthermore, albumin is known to have higher affinity for hydrophobic particles and has 
been reported to increase circulation time of NPs by limiting opsonization (e.g., adsorption 
of IgG)11,18 given the dysopsonic nature of this protein. Thus, the hypothesis to favorably 
tune the corona was tested via covalent attachment of HSA on anti-ICAM-1 coated PLGA 
particles to improve their blood flow adhesion efficiency. Anti-ICAM-1-coated particles 
were chosen for the HSA attachment experiment since no significant benefit was observed 
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for this ligand type at a high ligand density and thus, this corona-tailoring approach could 
offer an alternative avenue to improve adhesion of these particles. However, no significant 
improvement in adhesion of PLGA-HSA-anti-ICAM-1 coated particles was observed over 
the non-HSA conjugated particle control. This could be due to the fact that additional 
surface albumin molecules are needed to generate an effect, given that the surface is still 
largely dominated by NeutrAvidin. In a recent study, immunoglobulin proteins were 
covalently attached to silica nanoparticles in an effort to increase targeted uptake to 
macrophages, but this strategy was impeded by other corona proteins and no increase in 
uptake was observed for Ig-coated spheres, suggesting than a corona layer deposits on top 
of the protein ligand causing interference in binding efficiency19. Thus, it may be the case 
here that the altered corona which forms on the surface of HSA-coated particles still 
adsorbs a sufficient amount of critical “negative” proteins (e.g., immunoglobulins) in the 
corona, resulting in an unfavorable immunoglobulin-rich corona and no benefit in PLGA 
particle adhesion between blood and RBCs-in-VB.  
As observed in Fig. 5.1 and 5.2B, the trend in % control adhesion at lower to 
moderate site densities suggests PCL may be a better candidate as a VTC for vascular 
diseases. However, it is important to note that PLGA has been observed to maintain a 
higher bioavailability than PCL in vivo20, and PLGA has more favorable degradation 
profiles for drug delivery applications. 
5.4 Conclusions 
This work explored the role of material type—particularly, biodegradable 
polymers—on the previously observed plasma-induced negative adhesion effect observed 
primarily with PLGA microspheres. Here, it is observed that biodegradable polyesters do 
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behave differently; namely, that PCL enjoys minimal reduction in blood flow relative to 
PLGA and PLA, potentially a result of differences in hydrophobicity causing the observed 
reduced Ig adsorption on PCL spheres. Although the adhesion efficiency for sLea particles 
of all materials was largely abated at high ligand density, lower densities may translate 
better for in vivo targeting. Overall, PCL was more robust than the other polyesters studied 
here in terms of blood flow adhesion efficiency but there are other differences between 
these polymers such as degradation rate and bioavailability which need to be considered. 
Lastly, covalent attachment of dysopsonins (i.e., HSA) onto PLGA did not repel the impact 
of the corona; however, further tuning of surface protein density and testing of other protein 
candidates may prove beneficial in this approach. 
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CHAPTER 6: THE IMPACT OF ANTICOAGULANT ON CORONA-INDUCED 
NEGATIVE ADHESION ON DRUG CARRIERS IN BLOOD FLOW 
 
ABSTRACT 
Upon injection of vascular-targeted drug carriers (VTCs) into blood, plasma proteins 
rapidly coat the surface forming the protein corona. Previous work has observed that the 
protein corona can impact a variety of drug delivery phenomena, including targeted drug 
carrier adhesion to the vascular wall. To date, the bulk of the work evaluating the impact 
of the protein corona on drug carrier functionality has employed various mediums, 
including bovine serum, cell media, human serum, and anticoagulated plasma. 
Anticoagulants are known to influence the proteomic profile of plasma and as such may 
mediate the previously observed plasma-related carrier effects. In this work, we explore 
the role of plasma anticoagulant on altering the protein corona impact on the specific 
adhesion of targeted drug carriers to the vascular wall via an in vitro parallel plate flow 
chamber assay. Specifically, we characterized the binding efficiency of model carriers of 
various material types to activated HUVECs in heparinized, citrated, and non-
anticoagulated blood flows. Particle adhesion to activated HUVECs is substantially 
reduced in blood flow, particularly in heparinized and serum blood flow, depending on the 
targeting ligand density and material type. 
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6.1 Introduction 
Previously, rapid plasma protein adsorption onto poly(lactic-co-glycolic) acid 
(PLGA)-based VTCs was shown to drastically reduce their adhesion efficiency to inflamed 
endothelium in human blood flow; however, these effects were mainly non-existent for 
polystyrene (PS), silica (Si), and titanium dioxide (TiO2) particles
1–3. This plasma protein 
adhesion effect was due to unique protein corona formed on PLGA; namely, PLGA VTCs 
acquired specific immunoglobulin (Ig) sized (~150 kDa) antibody proteins1, which were 
not significantly present on PS particles. However, this previous work may be limited since 
all assays were performed with anticoagulated (citrated) plasma. Although serum (no 
anticoagulant) and anticoagulated plasma are both routinely used to assess NP-protein 
interactions, these mediums have their own unique protein composition and this is known 
to influence the impact of the protein corona on cellular uptake4–6. Indeed, a recent study 
comparing the protein corona formation on silica NPs exposed to human plasma and serum 
observed that plasma-exposed silica NPs experienced increased cellular uptake relative to 
serum exposed silica NPs6, which was linked to specific adsorption of  opsonic coagulation 
proteins such as fibrinogen onto plasma-exposed but not serum-exposed NPs (fibrinogen 
is depleted in serum).  However, the role of anticoagulant on protein corona formation and 
its potential role in prescribing VTC adhesion efficiency to the vascular wall in human 
blood flow remains relatively unknown. This work seeks to elucidate how different 
anticoagulants or their absence modulates VTC adhesion efficiency in human blood flow 
via differences in the particle protein corona.   
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6.2 Results 
6.2.1 Impact of anticoagulant on the adhesion efficiency of various VTC materials 
 The main objective here is to evaluate how different anticoagulants and their 
absence potentially alter the impact of the plasma protein corona on VTC adhesion to the 
vascular wall in human blood flow. Specifically, PLGA, PLA, PCL, PS, and Si particle 
adhesion was evaluated in a PPFC assay with heparinized or ACD anticoagulated whole 
blood (WB) or RBCs-in-Serum (no anticoagulant) and compared to adhesion of particles 
in RBCs-in-VB. Biodegradable PLGA, PLA, and PCL are primarily explored here while 
PS and Si serve as controls in our assays to allow comparison to existing literature. ACD 
and heparin are chosen as they both are commonly used anticoagulants. ACD chelates 
calcium ions, thus preventing the clotting process, whereas heparin acts by binding to 
antithrombin III, causing inactivation of thrombin. VTC diameters ranged from ~400-700 
nm as previously listed in Table 5.1. Table 6.1 lists the average sLea ligand site density for 
the various VTC materials.  
Figure 6.1 shows the adhesion levels of all sLea-targeted particles to an activated 
HUVEC monolayer in flow of anticoagulated WB (heparin or ACD) or with RBCs-in-
Serum (no anticoagulant) relative to the adhesion of the same particles in RBCs-in-VB 
(control). For PLGA particles, vascular wall adhesion observed in ACD WB was 75% 
lower than the adhesion level of the same particles observed in RBCs-in-VB. A similar 
reduction in adhesion was obtained for PLGA in heparinized WB and RBCs-in-Serum, 
where the levels of adhesion observed were 74% and 89% lower than the control (Figure 
6.1), respectively. In contrast, the adhesion levels for PS, Si, and PCL particles in ACD 
WB were only moderately lower relative to the control (< 40% reduction).  However, 
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similar to PLGA and PLA, significantly lower adhesion occurred for these materials in 
RBCs-in-Serum, where ~80% reduction was observed relative to the control. Heparinized 
WB resulted in low adhesion compared to the control for PLA and PS (>80% reduction), 
but Si and PCL showed moderate effects with less than 60% adhesion reduction observed.  
Table 6.1 VTC ligand density quantification 
 
Material sLea density (sites µm-2) S.E. 
PLA, PLGA 3500 700 
PLGA (“high”) 15300 900 
Si 4400 200 
PS 6000 300 
PCL 2200 500 
PCL (“moderate”) 7100 1200 
 
6.2.2 Evaluation of HUVEC adhesion of various VTCs in anticoagulant-free WB 
flow 
Although serum is anticoagulant free, the clotting process depletes coagulation 
factors, fibrinogen, fibronectin, and may artificially raise the level of other proteins relative 
to that in anticoagulated plasma. One medium that may provide a better model of human 
blood in vivo is anticoagulant-free (ACF) whole blood. For these assays, blood without 
anticoagulant was drawn from healthy donors and used immediately in flow assays. As 
shown in Figure 6.2, PS, Si, PLGA, and PCL VTCs experienced ~80% reduction and PLA, 
95% reduction relative to their respective control assay. Overall, the low adhesion relative 
to RBCs-in-VB observed in ACF WB is in line with the low adhesion observed in RBCs-
in-Serum (no anticoagulant added) for all VTC material types. Interestingly, PLGA 
performs significantly better in ACF blood (~80% reduction) compared to RBCs-in-Serum 
(~90% reduction).  
102 
 
 
Figure 6.1. PPFC assay with VTCs in various anticoagulants: HUVEC adhesion (% 
relative to RBCs-in-VB Control) for PLGA, PLA, PS, Si, and PCL VTCs in ACD 
WB, heparinized WB, and RBCs-in-Serum relative to RBCs-in-VB after 5 min of 
flow at a shear rate of 200s-1. Particle concentration was fixed to 1 x 106 particles 
mL-1. * = p<0.01 relative to ACD-WB trial for given material via one-way ANOVA 
with Tukey post-test. n ≥ 4. ** = p<0.01 relative to heparinized WB trial for given 
material via one-way ANOVA with Tukey post-test.  
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Figure 6.2 PPFC assay with VTCs in ACF WB: HUVEC adhesion (% relative to RBCs-
in-VB Control) for PLGA, PLA, PS, Si, and PCL VTCs in Anticoagulant-free 
WB relative to RBCs-in-VB after 5 min of flow at a shear rate of 200s-1. Particle 
concentration was fixed to 1 x 106 particles mL-1. * = p<0.01 relative to 
Anticoagulant-free WB trials relative to all other VTC materials.  
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6.2.3 Impact of ligand density in mitigating plasma-associated VTC adhesion 
reduction 
Previous work observed that the targeting ligand density can play a role in 
mitigating the extent of the negative impact of the plasma protein corona on the adhesion 
of PLGA VTCs in ACD treated blood1. We explore this possibility here for particle 
adhesion in all the different blood conditions. As shown in Figure 6.3, PLGA particles with 
high ligand density (~15,000 sLea sites µm-2) displayed improved adhesion in ACD WB, 
exhibiting only 30% reduction compared to the control. In addition, ~20% improvement in 
adhesion relative to the control was achieved in heparinized WB with the high ligand 
density. Increasing the site density of PLGA VTCs exposed to serum or ACF WB did not 
improve their adhesion levels relative to the control. Interestingly, having a moderately 
higher ligand density (~7000 sLea sites µm-2) on PCL did not significantly impact their 
relative adhesion in ACD WB, heparinized WB, or serum (Figure 6.4). Further increases 
in the sLea site density of PCL particles to ~15,000 sLea sites µm-2 offered no additional 
adhesion recovery when tested in ACD WB (see Chapter 5).  
6.2.4 Evaluation of differences in VTC protein corona relative to blood 
characteristic 
The presented results thus far showed high reduction of VTC adhesion in RBCs-
in-Serum relative to ACD or heparinized WB. Although serum and plasma are both 
routinely used to characterize NP uptake and other relevant drug delivery processes, the 
protein composition of each is different, and in particular, serum does not contain 
fibrinogen and has lower concentration of other clotting factors and cell adhesion proteins 
(e.g., fibronectin), which could significantly change the protein corona formed on VTCs7,8.  
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Figure 6.3. PPFC assay with high ligand density PLGA VTCs: HUVEC adhesion (% 
relative to RBCs-in-VB Control) for high ligand density PLGA VTCs (~15,000 sites/µm2) 
in ACD WB, heparinized WB, RBCs-in-Serum, and Anticoagulant-free WB after 5 min of 
flow at a shear rate of 200s-1. Particle concentration was fixed to 1 x 106 particles mL-1. * 
= p<0.01 relative to ACD-WB trial via one-way ANOVA with Tukey post-test. n ≥ 4. ** 
= p<0.01 relative to heparinized WB trial via one-way ANOVA with Tukey post-test.  
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Interestingly, all VTCs exhibit similar zeta potential upon soaking with plasma and serum 
(Figure 6.5), which suggests that differential adhesion of VTCs exposed to plasma and 
serum flow stems from the formation of unique protein coronae in these mediums rather 
than electrostatic interactions.  To test this hypothesis, the protein corona on PLGA VTCs 
is profiled using SDS-PAGE for particles exposed to serum, heparinized plasma, and ACD 
plasma for ~10 minutes at 37°C.  Figure 6.6 shows an image of the SDS-PAGE gel for 
which there is a notable increase (2.0 +/- 0.4 folds via ImageJ) in the intensity of the band 
at the 150 kDa mark for the corona acquired from serum versus ACD plasma. We 
previously reported that the intensity of the 150 kDa protein band, which mainly contains 
Igs, directly correlated with the extent of the negative impact of plasma proteins on VTC 
adhesion efficiency. The heparinized plasma corona also shows some unique differences 
compared to ACD plasma and serum, particularly in the ~100-150 kDa range but overall 
appears to exhibit the least amount of protein adsorption.   
6.3 Discussion 
The data presented in this work shows that anticoagulant plays a significant role in 
modulating the impact of the protein corona on the adhesion efficiency of VTCs to 
HUVECs in human blood flow, and the extent of these corona-induced effects depend on 
the VTC material type and ligand density. In particular, all VTC types exhibited low levels 
of adhesion in RBC-containing serum flow relative to anticoagulated blood flow. We 
conclude that this observation is due to increased large protein adsorption (i.e., Igs) on 
serum relative to plasma exposed VTCs based on our previous work linking Igs as major 
players in driving corona-induced adhesion reduction1,3. Enhanced Ig adsorption in the 
serum versus plasma corona observed here with PLGA has also been observed on solid 
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lipid nanoparticles in a different study, potentially a consequence of the differential 
proteomic profile of these two mediums favoring Ig adsorption in serum relative to 
plasma9.  
Similar to the RBCs-in-Serum trials, low particle adhesion was observed in ACF 
WB relative to anticoagulant-containing WB trials. The main difference between RBCs-
in-Serum and ACF WB is that for serum, the clotting process artificially elevates levels of 
various proteins as well as attenuates the concentration of others7,10. However, with the 
exception of complement factor H precursor (~150 kDa), proteins with elevated levels in 
serum typically fall within a lower molecular weight range, typically between 10-40 kDa. 
Thus, it is likely that the critical “negative” proteins including Igs in the ~150 kDa size 
range are conserved through the clotting process, and likely not altered in concentration 
between ACF and RBCs-in-Serum. Moreover, Igs such as IgG have been quantified in 
human serum and plasma via IgG ELISA kits (Abcam, ab100547) and in general are 
observed to be highly similar in concentration, typically between a range of 6-15 mg mL-1 
11. Thus, the negative impact of the corona on adhesion between ACF WB and RBCs-in-
Serum is likely not due to artifacts of the clotting process affecting the Ig concentration. 
While the negative impact of plasma proteins on VTC adhesion was tempered in 
anticoagulated blood, VTCs adhesion was significantly lower with heparinized WB as the 
flow medium compared to ACD WB. This observation is not surprising since heparin and 
ACD anticoagulants act by different mechanisms and can have profound impacts on the 
overall plasma composition7,12,13. Heparin (which acts to prevent coagulation by catalyzing 
inactivation of thrombin by antithrombin III) binds to a significant number of other plasma 
proteins14, and the binding of heparin/heparin sulfate to these “heparin-binding” proteins 
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Figure 6.4. PPFC assay with high ligand density PCL VTCs: HUVEC adhesion (% relative 
to RBCs-in-VB Control) for high ligand density PCL VTCs (~7,000 sites/µm2) in 
ACD WB, heparinized WB, and RBCs-in-Serum after 5 min of flow at a shear rate 
of 200s-1. Particle concentration was fixed to 1 x 106 particles mL-1. * = p<0.01 
relative to ACD-WB trial via one-way ANOVA with Tukey post-test. n ≥ 4. ** = 
p<0.01 relative to heparinized WB trial via one-way ANOVA with Tukey post-test.  
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Figure 6.5. Zeta potential measurements for sLea-coated VTCs of various materials. VTCs 
were soaked in the various medium (viscous buffer, ACD plasma, heparinized 
plasma, serum) and washed with D.I. water. Measurements were then performed in 
D.I. water using a Malvern Zetasizer instrument. Concentration ranged from 0.65 
– 2.5 × 107 particles mL-1. 
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Figure 6.6. SDS-PAGE: Characterization of surface bound protein coronae formed on 
PLGA VTCs exposed to VB, plasma (ACD, heparin), and serum. Lane 1: molecular 
weight standard, Lane 2: corona from VB soak, Lane 3: corona from ACD plasma 
soak, Lane 4: corona from heparinized plasma soak, and Lane 5: corona from serum 
soak. 
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can modify their activity, metabolism, and concentration15,16. Anticoagulants such as ACD, 
chelate calcium and unlike heparin, are not expected to induce protein-protein binding to 
the same extent. In addition, a study by Kim et al. identified a variety of proteins with 
increased concentration in heparin versus citrated plasma, including α2-macroglobulin, 
haptoglobulin precursor, Apo-AI, Apo J precursor, and complement factor H precursor10. 
Indeed, recent work by Schöttler et al. has observed slight differences in the protein corona 
between polystyrene NPs exposed to heparin and citrated blood, where compositional 
increases in fibrinogen and decreases in vitronectin were observed in citrate relative to 
heparin corona, and these particles exhibited differential uptake in HeLa cells and 
macrophages5. The corona profile observed on PLGA particles here shows differences in 
heparin versus ACD exposed particles, which could explain the differential adhesion 
efficiency of VTCs in heparinized versus ACD WB flow.  Specifically, the adsorption of 
Igs (150 kDa mark) and other large proteins which have been linked to reduced adhesion 
in blood flow are less prominent in the heparin versus citrate blood derived corona, despite 
the fact that the adhesion reduction was higher in heparin compared to  ACD WB1,3. Thus, 
it may be the case that other proteins are involved in causing enhanced adhesion reduction 
of VTCs in heparin versus citrate blood flow. The main unique band in the heparin lane is 
between 100 and 150 kDa, possibly a form of haptoglobulin (~100 kDa) or complement 
factor H (~140 kDa), given the fact these proteins have been identified to be in higher 
concentration in heparin versus citrated plasma, potentially leading to increased adsorption 
in the corona for PLGA particles10.   
The impact of anticoagulant on protein corona-induced VTC adhesion reduction 
also depended on material type.  Specifically, PCL and Si outperformed all other materials 
112 
 
in both ACD and heparinized WB, suggesting these materials are generally more resistant 
to the negative impacts of the plasma protein corona on VTC adhesion efficiency in blood 
flow. Overall, PLGA and PLA adhesion profiles closely resembled each other, where large 
reductions (>75%) were observed in all mediums tested. However, the material 
dependence of the impact of corona-induced effects observed in ACD and heparinized WB 
were eliminated in RBCs-in-Serum and ACD WB trials, where high percent reductions 
(>75%) in adhesion were observed regardless of the material type. 
6.4 Conclusion 
This study has revealed that the absence of anticoagulant magnifies the negative 
adhesion impact of the protein corona via enhanced Ig adsorption on drug carriers relative 
to that observed in anticoagulated blood flow. This work suggests that anticoagulated 
whole blood may result in an overestimation of drug carrier adhesion efficiency with 
human blood in vivo, given the similar low adhesion observed in both RBC-containing 
serum and ACF WB flow for all particle types tested. Furthermore, the magnified effects 
of the protein corona in the absence of anticoagulant will likely persist despite an increased 
ligand density, suggesting that the corona in serum or ACF WB may need to be altered via 
use of hydrophilic coatings or possibly proteins absent in serum (i.e., fibrinogen) as a 
possible avenue to counteract the negative effect of enhanced serum Ig adsorption and 
improve adhesion efficiency. Further studies seek to explore a combination of approaches 
including covalent protein attachment, particle density, and shape to improve the adhesion 
efficiency of PLGA and other biodegradable drug carriers in human blood flow assays.  
Lastly, an inherent limitation of this work stems from the use of in vitro assays with 
blood outside the body. This system, although a predictive indicator of human blood in 
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vivo, likely does not fully capture the landscape for protein adsorption and expected 
binding efficiency in a clinical setting. Next steps to better predict adhesion efficiency in 
human would likely involve in vivo evaluation of drug carriers in a porcine model, as we 
have previously identified this species to be highly comparable to human with regard to 
corona-associated adhesion effects on drug carriers.  
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CHAPTER 7: CONCLUSIONS, FUTURE STUDIES, AND COMMENTS 
 
A bulk of the work in the final section of this chapter is published as Sobczynski, D. J. et 
al. Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted 
drug delivery systems. Therapeutic Delivery 6, 915-934 (2015). 
 
7.1 Conclusions and Major Contributions 
  
Vascular targeting remains an important and highly beneficial alternative treatment 
strategy over systemic drug administration. Vascular targeting of particulate drug carriers 
offers vast potential for reduced side effects, improved drug bioavailability, and increased 
local drug concentration, resulting in a lower dose required to achieve efficacy. In addition, 
several diseases such as atherosclerosis, cancer, and arthritis involve vascular endothelial 
cell dysregulation, allowing for unique targeting opportunities for VTCs. Although 
vascular targeting of drug carriers is an attractive approach, current targeting formulations 
for vascular diseases still cause a host of deleterious side effects and only a small fraction 
of the dose reaches the targeted cells of interest. Understanding the complexity of drug 
carrier transport and adhesion in blood flow may provide critical insight into improving 
the specificity and efficiency of vascular-targeted carriers.  
Blood vessel wall inflammation is common in the early stage of many vascular 
diseases and is chosen as the disease model for the in vitro flow chamber assays. It was 
observed that the adhesion of targeted PLGA carriers to E-selectin on endothelial cells in 
human blood flow is significantly reduced due to the presence of plasma proteins which 
are thought to obstruct and/or weak ligand-receptor interactions at the wall. This result was 
rather surprising as other materials did not demonstrate these issues when exposed to 
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plasma. Furthermore, the low adhesion of PLGA in blood flow suggests that it is largely 
sub-optimal with regard to adhesion efficiency. These extent of PLGA adhesion fouling in 
blood flow depended on the surface ligand density, human blood donor, and flow 
magnitude and profile. Plasma immunoglobulins (Igs) were identified as critical negative 
proteins limiting PLGA adhesion efficiency. This may be due to the size and affinity of 
these proteins for PLGA.  
In Chapter 4, the role of Igs is explored in more detail via use of IgG and IgA 
depletion columns designed to tease out the contributions of these specific Ig proteins on 
corona-induced negative adhesion of PLGA in blood flow. Overall, depletion of IgG alone 
did not result in adhesion recovery, but the removal of all Ig’s (e.g., IgM, IgA, IgD, IgE) 
consistently showed nearly full recovery in adhesion compared to particles soaked in PBS 
buffer. Re-addition of enriched IgA fraction (also containing IgG and IgM) to depleted Ig’s 
plasma resulted in knockdown of the adhesion, confirming the importance of this protein 
in orchestrating corona-induced adhesion reduction of PLGA particles since addition of 
IgG alone did not cause adhesion knockdown. However, IgA is not exclusively responsible 
for the effect since depletion of this protein from plasma did not result in full adhesion 
recovery. These results are critical as they demonstrate corona-induced effects to be 
prescribed by individual proteins, rather than the “shell effect” which has been previously 
discussed in the literature. In addition, this work could be implemented to help improve 
prediction of therapeutic potential across different individuals. Specifically, Ig’s 
concentration or composition could serve to indicate the degree of targeting specificity 
expected for a VTC.  
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Although PLGA is well-studied and convenient for utility in drug delivery for 
several reasons, it is among a class of biodegradable polyesters which also includes the 
homopolymer PLA and PCL. These polymers are also used for drug delivery and tissue 
engineering applications, and thus it is important to explore how these other biodegradable 
materials (i.e., PLA, PCL) behave in blood flow relative to PLGA. In Chapter 5, it is 
observed that PCL particles outperform PLGA and PLA in terms of blood flow adhesion 
efficiency, defined as the ratio of particle adhesion in blood divided by plasma-free blood 
(RBCs-in-VB). Employment of high ligand density on particles for these materials 
significantly recovered the adhesion in blood flow; however, PCL is still attractive as this 
material exhibits mild adhesion reduction even at lower site densities, which may be 
optimal for targeting in vivo. Dependence of VTC adhesion on material type observed here 
is likely linked to hydrophobicity, as this parameter is critical to corona formation. In 
addition, reduced Ig adsorption is observed on PCL relative to PLGA and PLA, which 
supports the hypothesis that plasma Ig adsorption drives low adhesion efficiency of drug 
carriers. This work also points out the importance of material type (linked to 
hydrophobicity) and suggests that the optimal polymer for vascular wall adhesion be 
hydrophobic despite widespread evidence that increasing hydrophobicity leads to lower 
circulation time and enhanced protein adsorption.  
Up to this point, all assays have employed acid-citrate dextrose (ACD) as the 
plasma anticoagulant. The selection or absence of anticoagulant in blood causes drastic 
changes to the plasma proteome, which can thus influence cellular processes such as uptake 
via differences in the corona formed in plasma versus serum (no anticoagulant) or ACD 
plasma versus heparin, another common anticoagulant. Overall, it is observed that the 
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absence of anticoagulant enhances the extent of corona-induced adhesion reduction on 
PLGA as well as other materials. Furthermore, in the absence of anticoagulant (i.e., serum, 
non-anticoagulated blood flow) all materials exhibit high levels of reduction relative to 
plasma free blood (RBCs-in-VB). This work suggests that particle adhesion with human 
blood in vivo will be significantly hindered compared to that observed with anticoagulated 
blood in vitro. Furthermore, no significant benefits in adhesion were observed in non-
anticoagulated blood flow even with high targeting ligand density.  
7.2 Future studies 
 This dissertation has elucidated the role of the protein corona on drug carrier 
adhesion in human blood flow to inflamed human endothelial cells via in vitro flow 
chamber assays. In addition, the impact of specific proteins in orchestrating negative 
adhesion on PLGA drug carriers was explored via a combined effort through SDS-PAGE, 
mass spectrometry, ELISA, and plasma protein depletion studies. However, there are 
several directions in which the role of the protein corona could be expanded and further 
developed to better understand its impact in vascular targeted drug carrier adhesion: 
1. Test the adhesion of targeted fluorescent PLGA and PCL drug carriers in vivo 
using a porcine model as this animal has been identified to closely match the 
human system in regard to protein corona adhesion effects. 
2. Test PLGA particle adhesion with pre-formed porcine coronae in vivo compared 
to in vitro in RBCs-in-VB flow medium. 
2.1. Evaluate porcine corona formed in vivo and in vitro on PLGA via SDS-PAGE. 
2.2. Identify key differences in corona profile via mass spectrometry. 
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2.3. Perform similar experiment with human blood, obtaining anticoagulant-free WB 
to pre-form in vivo corona and facilitate particle collection via addition of 
anticoagulant.  
3. Optimize a “forced corona” approach via covalently attaching proteins and 
coatings to particle drug carrier surfaces in effort to improve adhesion in serum 
flow. 
3.1. Fibrinogen and fibronectin are known to be at least partially depleted in serum and 
have been identified to have adhesive properties making these proteins attractive 
candidates. 
3.2. Explore carbohydrate coatings such as hydroxyethyl starch or zwitterions which 
have been identified to severely mitigate any protein adsorption and its associated 
effects. 
3.3. Use mass spectrometry to obtain a library of potential “adhesion-positive” proteins 
found on PS and PCL but absent from PLGA and PLA surface coronae. 
3.4. Compare serum and non-anticoagulated blood flow adhesion in vitro between 
unmodified PLGA and PLGA coated with adhesive proteins or carbohydrate 
coatings.  
3.5. Explore the plasma protein profile via SDS-PAGE and identify key sources of 
differential protein binding via mass spectrometry. 
4. Develop assays to better understand how the protein corona impacts drug carrier 
adhesion across different human donors. 
4.1. Explore depletion assays for other blood in other anticoagulants as well as serum 
(no anticoagulant). 
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4.2. Expand the number of human subjects tested to obtain a better understanding of 
how specific Ig protein concentration, composition, or affinity impacts adhesion 
of drug carriers 
4.2.1. Ig protein concentration and composition can be compared across donors 
via a standard sandwich ELISA. 
4.2.2. Differential affinity of specific donor Ig proteins for polymer particles could 
be explored via a modified ELISA assay with nanoparticle-coated wells.  
4.2.3. Flow cytometry or western blotting of plasma or serum-soaked particles 
exposed to different donors could also be implemented to gauge the relative 
affinity of donor specific IgG or other Igs for the nanoparticle surface. 
5. Explore the adhesion of particles in serum from patients on anticoagulant therapy with 
the goal to understand how these therapies may impact targeted drug carrier adhesion 
in blood flow. 
7.3 Concluding thoughts, comments, and potential directions for the field 
This dissertation has revealed key insight into intelligent design of vascular-
targeted drug carriers. Specifically, it has been observed that the plasma protein corona is 
critical in prescribing the adhesion efficiency of drug carriers to the vascular wall in blood 
flow. This initially may come as a surprising result, given that plasma protein adsorption 
has typically been identified to play key roles in biodistribution, cell uptake, and other drug 
delivery processes which are largely biomolecular phenomena. Here, the plasma protein 
corona is observed to affect the biophysical phenomenon of drug carrier adhesion in blood 
flow which is typically controlled by forces, collisions, and receptor/ligand densities. In 
addition, this study has taken the idea of “corona-induced” particle adhesion reduction to 
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a new level by identifying specific types of proteins which alone seem to dominate the 
effect. Specifically, the work suggests that the impact of the protein corona on 
biodegradable drug carriers is driven by a single protein class; namely, immunoglobulins. 
This observation could prove to be of great value in that it offers a specific avenue to 
modulate drug carrier adhesion to the endothelium; specifically by preventing IgA and IgM 
adsorption. Furthermore, by identifying which proteins control this unwanted adhesion 
reduction of polymeric drug carriers, the affinity of a particle for IgA, IgM, and potentially 
other Igs determined via ELISA, western blotting, or SDS-PAGE opens the possibility of 
using the corona to “diagnose” and predict drug carrier adhesion efficiency in blood flow. 
The affinity of a particular particle may depend on human donor and thus may pave the 
way for a personalized medicine approach. The corona may prove useful to predict drug 
carrier adhesion efficiency based on its propensity to adsorb certain types of proteins 
known to negatively affect drug delivery processes such as vascular wall adhesion.  
This dissertation has shown that specific proteins control the targeting efficiency of  
drug carriers; specifically, large molecular weight immunoglobulins weaken the adhesion 
kinetics of drug carriers in blood flow. Although the natural instinct to combat this issue 
would involving elimination of the corona, it may also be interpreted in a different light; 
namely, tailoring the corona to potentially assist and improve VTC targeting efficiency. 
Indeed, the literature view of the impact of the protein corona on drug delivery processes, 
which has classically been viewed as an unwanted, negative phenomenon, has observed a 
shift in the last four to five years to a more positive outlook as it may hold an incredible 
potential to be exploited to direct particles to specific cells or regions of interest in the 
body1. For example, NPs that preferentially adsorb apolipoproteins, such as apoE, resulted 
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in enhanced cellular uptake by brain capillary endothelial cells. This was achieved by 
coating polybutyl cyanoacrylate NPs with a surfactant coating, polysorbate 802–5. In 
addition, uptake of titanium dioxide NPs by A549 human lung epithelial cells was 
enhanced in the presence of FBS, due to surface adsorbed vitronectin protein6. Other 
studies have also revealed that particles of the same material but different surface properties 
can adsorb similar coronas but interact with cells by completely different internalization 
pathways. Specifically, anionic PS and cationic PS NPs incubated with FBS showed nearly 
identical protein coronas (mainly adsorbed BSA), yet the anionic NPs interacted with 
monkey kidney epithelial cells via the natural albumin receptor, whereas cationic NPs 
interacted with scavenger receptors, attributed to a denaturing of BSA by cationic NPs7. 
The redirection of NP-cell interaction as a result of the protein corona has also been 
observed in comparing uptake of serum-coated vs uncoated PS NPs, where the presence of 
serum resulted in NP uptake via phagocytosis, rather than clatherin-mediated 
endocytosis/micropinocytosis for the bare NPs8. In general, NPs that adsorb 
immunoglobulin and complement result in internalization by phagocytes, thus promoting 
macrophage uptake. The protein corona protects the cell from damage compared to bare 
NPs, as the corona-adsorbed particle minimally affects cell membrane integrity. However, 
these effects show protein-specific dependence, as carbon nanotubes (CNTs) coated with 
γ-globulins resulted in damaged cell membranes whereas fibrinogen-coated CNTs do not 
9. Thus, the adsorbed NP-protein corona has abilities to modulate cell uptake, adhesion, 
and cell membrane integrity. Of course, other particle parameters such as zeta potential and 
surface morphology can further confound these results.    
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Harnessing the enhanced uptake features of protein-coated NPs could be used to 
direct the VTC to the cell of interest. This method of thinking considers the protein corona 
as a natural targeting mechanism, which can be tailored to enhance association with certain 
cells depending on the physicochemical properties of the NP. In general, hydrophobic NPs 
adsorb more proteins to mask their surface from water and to absorb proteins that induce 
uptake by macrophages 10.  However, as an example of more directed corona-targeting, the 
specific corona surrounding N-isopropylacrylamide-co-N-tert-butylacrylamide 
(NIPAM/BAM) copolymer NPs shows enhanced vitronectin adsorption, which leads to 
enhanced cellular uptake via the αVβ3 integrin, an overexpressed receptor in inflamed 
endothelium and cancer cells 11. If one aims to use the corona as a targeting mechanism, 
then there must be control over the composition in vivo. In this light, the plasma protein 
corona is a worthy candidate to enhance targeting efficiency of drug carriers and some 
current studies have begun developing models for predicting cell association based on NP-
corona features12. It may also prove advantageous to develop high-throughput screening 
assays of various drug carrier material types to obtain a more global understanding of 
corona variations and use this information to design “smart” VTCs capable of adsorbing a 
specific protein corona for a particular drug delivery application.     
The protein corona may also play a fundamental role in development of 
personalized medicines. Recently, a study revealed that NPs coated with plasma proteins 
of patients with various diseases resulted in unique corona compositions13. The 
individualized corona may prove to be a useful avenue to pursue for personalized medicine 
as biological interactions are heavily dependent on the corona formation. Specific NP 
features may be employed in blood of a certain disease in order to attract specific proteins 
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for enhanced cellular-targeting/uptake. Further research will likely assess different 
materials and properties of NPs with the goal of predicting the corona profile based on the 
chosen NP properties and plasma source features. Furthermore, optimal VTC targeting and 
uptake properties can be clarified by investigating these properties for NPs exposed to 
plasma from a cancer patient.   
 In this dissertation, the impact of the protein corona on VTC adhesion in blood flow 
was observed to negatively impact the targeting efficiency and it is certainly a worthwhile 
endeavor to seek the use of zwitterionic or carbohydrate-based coatings as avenues to 
substantially eliminate the formation of the corona and ideally restore the adhesion 
efficiency. However, it remains to be seen whether the protein corona can actually be 
eliminated completely in vivo and thus a drug delivery vehicle may always form a corona 
regardless of novel attempts to prevent its formation.  With this in mind, the idea of tuning 
the corona to prevent adsorption of immunoglobulins or combat its presence via adsorption 
of small molecular weight dysopsonins may be a useful alternative. As discussed in this 
chapter, the idea of exploiting the corona by tuning its properties has shown a significant 
growth and interest in the literature. The use of the protein corona as a “built-in” targeting 
mechanism is a fascinating and exciting new direction for development of drug delivery 
systems. Furthermore, this field is in its infant stages and will only grow further as new 
studies develop. The potential of the protein corona is vast as it holds utility in drug carrier 
targeting efficiency, personalized medicine, and diagnostics of drug carrier formulations.     
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